<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hypofractionated radiation therapy for early breast cancer - Hickey, BE - 2016 | Cochrane Library</title> <meta content="Hypofractionated radiation therapy for early breast cancer - Hickey, BE - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003860.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hypofractionated radiation therapy for early breast cancer - Hickey, BE - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003860.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003860.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Hypofractionated radiation therapy for early breast cancer" name="citation_title"/> <meta content="Brigid E Hickey" name="citation_author"/> <meta content="brigid.hickey@health.qld.gov.au" name="citation_author_email"/> <meta content="Melissa L James" name="citation_author"/> <meta content="Christchurch Hospital" name="citation_author_institution"/> <meta content="Margot Lehman" name="citation_author"/> <meta content="Phil N Hider" name="citation_author"/> <meta content="University of Otago, Christchurch" name="citation_author_institution"/> <meta content="Mark Jeffery" name="citation_author"/> <meta content="Christchurch Hospital" name="citation_author_institution"/> <meta content="Daniel P Francis" name="citation_author"/> <meta content="Queensland University of Technology" name="citation_author_institution"/> <meta content="Adrienne M See" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD003860.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/07/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003860.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003860.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003860.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Radiation Dose Hypofractionation; Breast Neoplasms [*radiotherapy, surgery]; Combined Modality Therapy [methods]; Dose Fractionation, Radiation; Mastectomy, Segmental; Radiation Injuries [complications, mortality]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003860.pub4&amp;doi=10.1002/14651858.CD003860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003860\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003860\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","pt","ja","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003860.pub4",title:"Hypofractionated radiation therapy for early breast cancer",firstPublishedDate:"Jul 18, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003860.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003860.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003860.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003860.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003860.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003860.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003860.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003860.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003860.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003860.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6707 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003860.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0153"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/appendices#CD003860-sec-0158"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/table_n/CD003860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/table_n/CD003860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hypofractionated radiation therapy for early breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Brigid E Hickey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0003">Melissa L James</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0004">Margot Lehman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0005">Phil N Hider</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0006">Mark Jeffery</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0007">Daniel P Francis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information#CD003860-cr-0008">Adrienne M See</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information/en#CD003860-sec-0168">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 July 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003860.pub4">https://doi.org/10.1002/14651858.CD003860.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003860-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003860-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003860-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003860-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003860-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003860-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003860-abs-0001" lang="en"> <section id="CD003860-sec-0001"> <h3 class="title" id="CD003860-sec-0001">Background</h3> <p>Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if the shorter treatment is as effective and safe as conventional radiation therapy. This is an update of a Cochrane Review first published in 2008 and updated in 2009. </p> </section> <section id="CD003860-sec-0002"> <h3 class="title" id="CD003860-sec-0002">Objectives</h3> <p>To assess the effect of altered radiation fraction size for women with early breast cancer who have had breast conserving surgery. </p> </section> <section id="CD003860-sec-0003"> <h3 class="title" id="CD003860-sec-0003">Search methods</h3> <p>We searched the Cochrane Breast Cancer Specialised Register (23 May 2015), CENTRAL (<i>The Cochrane Library</i> 2015, Issue 4), MEDLINE (Jan 1996 to May 2015), EMBASE (Jan 1980 to May 2015), the WHO International Clinical Trials Registry Platform (ICTRP) search portal (June 2010 to May 2015) and ClinicalTrials.gov (16 April 2015), reference lists of articles and relevant conference proceedings. No language or publication constraints were applied. </p> </section> <section id="CD003860-sec-0004"> <h3 class="title" id="CD003860-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of altered fraction size versus conventional fractionation for radiation therapy in women with early breast cancer who had undergone breast conserving surgery. </p> </section> <section id="CD003860-sec-0005"> <h3 class="title" id="CD003860-sec-0005">Data collection and analysis</h3> <p>Two authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial authors. </p> </section> <section id="CD003860-sec-0006"> <h3 class="title" id="CD003860-sec-0006">Main results</h3> <p>We studied 8228 women in nine studies. Eight out of nine studies were at low or unclear risk of bias. Altered fraction size (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not have a clinically meaningful effect on: local recurrence‐free survival (Hazard Ratio (HR) 0.94, 95% CI 0.77 to 1.15, 7095 women, four studies, high‐quality evidence), cosmetic outcome (Risk ratio (RR) 0.90, 95% CI 0.81 to 1.01, 2103 women, four studies, high‐quality evidence) or overall survival (HR 0.91, 95% CI 0.80 to 1.03, 5685 women, three studies, high‐quality evidence). Acute radiation skin toxicity (RR 0.32, 95% CI 0.22 to 0.45, 357 women, two studies) was reduced with altered fraction size. Late radiation subcutaneous toxicity did not differ with altered fraction size (RR 0.93, 95% CI 0.83 to 1.05, 5130 women, four studies, high‐quality evidence). Breast cancer‐specific survival (HR 0.91, 95% CI 0.78 to 1.06, 5685 women, three studies, high quality evidence) and relapse‐free survival (HR 0.93, 95% CI 0.82 to 1.05, 5685 women, three studies, moderate‐quality evidence) did not differ with altered fraction size. We found no data for mastectomy rate. Altered fraction size was associated with less patient‐reported (P &lt; 0.001) and physician‐reported (P = 0.009) fatigue at six months (287 women, one study). We found no difference in the issue of altered fractionation for patient‐reported outcomes of: physical well‐being (P = 0.46), functional well‐being (P = 0.38), emotional well‐being (P = 0.58), social well‐being (P = 0.32), breast cancer concerns (P = 0.94; 287 women, one study). We found no data with respect to costs. </p> </section> <section id="CD003860-sec-0007"> <h3 class="title" id="CD003860-sec-0007">Authors' conclusions</h3> <p>We found that using altered fraction size regimens (greater than 2 Gy per fraction) does not have a clinically meaningful effect on local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance, late toxicity or patient‐reported quality‐of‐life measures for selected women treated with breast conserving therapy. These are mostly women with node negative tumours smaller than 3 cm and negative pathological margins. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003860-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003860-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003860-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003860-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003860-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003860-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003860-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003860-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003860-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003860-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003860-abs-0004" lang="en"> <h3>Fraction size in radiation therapy for breast conservation in early breast cancer</h3> <p><b>Review question</b> </p> <p>We asked if giving fewer radiation treatments (using a higher radiation dose at each visit) was as effective as the conventional 25 to 30 radiation treatments for women with early breast cancer who have breast conserving therapy (keep their breast). </p> <p><b>Background</b> </p> <p>Breast cancer is the most common cancer diagnosed in women, with one in eight women in the United States and Australia, and one in nine women in the United Kingdom being diagnosed with the condition by age 85 years. Breast conserving therapy (removing the tumour but keeping an intact breast) has proven to be as effective as mastectomy (removing the breast tissue) in terms of survival for women with cancer confined to the breast (or the local lymph nodes, or both), as long as a five to six‐week course of radiation therapy is delivered. This involves 25 to 30 visits to a radiation oncology department. Without radiation therapy after breast conserving surgery there is a significant risk of breast cancer returning in the breast (local recurrence). Furthermore, for every local recurrence avoided with radiation, one death is avoided at 15 years. Many women prefer breast conservation which has resulted in an increased demand for radiation services. Giving fewer daily radiation treatments (fractions) would be beneficial to women if this has the same effect on tumour control and survival, and cosmetic outcome. In order to reduce the number of treatments, the radiation dose delivered per fraction is increased. This may also reduce demand on radiation resources and be more convenient for women. </p> <p><b>Study characteristics</b> </p> <p>Nine studies, involving 8228 women, were included in this review. Most of the women in the studies (91%) had tumours 3 cm or less in size, all had complete removal of the tumour on pathology and 68% had no evidence of cancer in their lymph nodes. Where the breast size was known, 83% had small or medium breasts. </p> <p><b>Key results</b> </p> <p>The evidence is current up to May 2015. Local recurrence was not different for women having fewer treatments (four fewer local relapses per 1000 (where the true value may be anywhere between 16 fewer to 10 more local relapses per 1000)). Breast appearance was not different for women undergoing fewer treatments (31 fewer fair/poor breast appearance per 1000 (where the true value may be anywhere between 59 fewer to 3 more per 1000 with fair/poor breast appearance)). Survival was not altered by having fewer treatments (13 fewer deaths per 1000 (where the true value could be between 31 fewer to 5 more deaths per 1000)) and there was no significant difference in late skin toxicity (4 more episodes of toxicity per 1000; where the true value may be anywhere between 14 fewer to 36 more episodes of toxicity per 1000) or radiation toxicity. Acute skin toxicity is decreased with fewer treatments (326 fewer events per 1000 (where the true value may be anywhere between 264 fewer to 374 fewer acute skin toxicity events per 1000)). This review indicates that for women who fit these criteria, using fewer radiation treatments after tumour removal gives the same cancer control, with less skin reaction at the time and the likely the same side‐effects in the long term. </p> <p><b>Quality of the evidence</b> </p> <p>We found high quality evidence for the following outcomes: local recurrence‐free survival, breast appearance, toxicity, overall survival and breast cancer‐specific survival. We found moderate quality evidence for relapse‐free survival, and no data for mastectomy rate (mastectomy may be required because of local recurrence or unacceptable treatment‐related toxicity) or costs. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003860-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003860-sec-0153"></div> <h3 class="title" id="CD003860-sec-0154">Implications for practice</h3> <section id="CD003860-sec-0154"> <p>In selected women with early breast cancer (with negative margins and size 3 cm or less, with small to medium sized breasts), shortened fractionation regimens are not detrimental for cancer‐related outcomes (no clinically meaningful difference with the use of altered fraction size. Clinically meaningful benefits or harms excluded for local recurrence‐free survival, overall survival, relapse‐free survival and breast cancer‐specific survival) and altered fraction size may be associated with a reduction in late radiation therapy toxicity. There still remains uncertainty about the effect of altered fraction size on ischaemic heart disease, although new radiation techniques, which avoid treating the heart, mean this of less importance. </p> </section> <h3 class="title" id="CD003860-sec-0155">Implications for research</h3> <section id="CD003860-sec-0155"> <p>There are a number of questions still unanswered with respect to costs and quality of life that relate to the use of altered fraction size in the treatment of early breast cancer for women undergoing breast cancer surgery. These questions are likely to be answered by both ongoing studies and future publications of completed studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003860-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003860-sec-0029"></div> <div class="table" id="CD003860-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women treated with breast conserving therapy for early breast cancer<br/> <b>Setting:</b> cancer centres<br/> <b>Intervention:</b> hypofractionated radiation therapy<br/> <b>Comparison:</b> conventionally fractionated radiation therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventionally fractionated radiation therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with hypofractionated radiation therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Local recurrence‐free survival (LR‐FS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/> (0.77 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7095<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000<br/> (54 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmesis<br/> assessed with fair/poor on 4‐point scale,<br/> follow‐up: range 42 months‐12 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.81 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2103<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1,000<br/> (252 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.80 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000<br/> (135 to 171) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late subcutaneous toxicity<br/> assessed with ≥ Grade 2 on 4‐point scale,<br/> follow‐up: median 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5130<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1,000<br/> (3 to 4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Breast cancer‐specific survival (BC‐SS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.78 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1,000<br/> (98 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relapse‐free survival (RFS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/> (0.82 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1,000<br/> (188 to 234) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mastectomy rate ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data with respect to subsequent mastectomy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The baseline risks for the control groups were calculated using 10‐year event data from the included studies<br/> <sup>2</sup> No blinding for assessment of subjective outcomes (for 5% of events only)<br/> <sup>3</sup>Statistical testing as well as examination of the forest plots suggested there was some heterogeneity </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003860-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003860-sec-0030"></div> <section id="CD003860-sec-0031"> <h3 class="title" id="CD003860-sec-0031">Description of the condition</h3> <p>This review is an update of a review previously published in the <i>Cochrane Database of Systematic Reviews</i> 2009, Issue 11 on fraction size in radiation therapy for breast conservation in early breast cancer. Breast cancer is the most common cancer diagnosed in women and the second most common cause of cancer death in women. The lifetime risk to age 85 years of being diagnosed with breast cancer for women living in Australia and the United States is one in eight, and one in nine for women living in the United Kingdom (<a href="./references#CD003860-bbs2-0043" title="Australian Institute of Health and Welfare &amp; National Breast Cancer Centre. Breast Cancer in Australia: an overview. No. 34. cat no. CAN 29. Vol. Cancer Series, Canberra: AIHW, 2006. ">AIHW 2006</a>; <a href="./references#CD003860-bbs2-0083" title="Office of National Statistics. Registrations of cancer diagnosed in 1993‐96, England and Wales. Health Statistics Quarterly1999;04:59‐70. ">ONS 1999</a>; <a href="./references#CD003860-bbs2-0088" title="RiesLA , EisnerMP , KosaryCL , HankeyBF , MillerBA , CleggL , et al. SEER cancer statistics review, 1973‐1999. National Cancer Institute. Bethesda, MD. seer.cancer.gov/cgi_bin/csr/1975_2004/search.pl#results. (accessed 31 August 2007). ">Ries 2004</a>). </p> <p>A significant change has occurred in the management of women with early breast cancer (cancer confined to the breast and nearby lymph nodes) over the last three decades. Previously most women with early breast cancer underwent removal of the whole breast (mastectomy). Evidence from several randomised controlled trials (<a href="./references#CD003860-bbs2-0061" title="FisherB , RedmondC , PoissonR , MargoleseR , WolmarkN , WickerhamL , et al. Eight year results of a randomized trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine1989;320(13):822‐8. ">Fisher 1989</a>; <a href="./references#CD003860-bbs2-0097" title="VeronesiU , BanfiA , SalvadoriP , LuiniA , SaccozziR , ZucaliR , et al. Breast conservation is the treatment of choice in small breast cancer: long‐term results of a randomised trial. European Journal of Cancer1990;26(6):668‐70. ">Veronesi 1990</a>) and a meta‐analysis of 36 trials (<a href="./references#CD003860-bbs2-0057" title="Early Breast Cancer Trialists' Collaborative group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomised trials. New England Journal of Medicine1995;333(22):1444‐55. ">EBCTCG 1995</a>) confirms that long‐term overall survival is equivalent using breast conserving treatment compared with mastectomy. Breast conserving treatment comprises removal of the portion of the breast containing the tumour followed by radiation therapy to the remaining breast tissue. Other studies have shown that quality of life is enhanced in women who undergo breast conserving treatment (<a href="./references#CD003860-bbs2-0044" title="Al‐GhazalSK , FallowfieldL , BlameyRW . Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. European Journal of Cancer2000;36(15):1938‐43. [PMID 11000574] ">Al‐Ghazal 2000</a>). Consequently, breast conserving treatment has become the recommended option for women with early breast cancer in many Western countries (<a href="./references#CD003860-bbs2-0078" title="National Breast Cancer Centre. Clinical Practice Guidelines for Management of Early Breast Cancer. Canberra: NH&amp;MRC, 2001:55. [Cat.No 0142926] ">NBCC 2001</a>; <a href="./references#CD003860-bbs2-0082" title="NIH consensusconference . The treatment of early breast cancer. Journal of the American Medical Association1991;265(3):391‐5. ">NIH 1991</a>). Breast conserving surgery now accounts for 70% of breast cancer operations in some series (<a href="./references#CD003860-bbs2-0051" title="ChouilletAM , BellCMJ , HiscoxJG . Management of breast cancer in southeast England. BMJ1994;308(6922):168‐71. ">Chouillet 1994</a>) and, as a result, demand for radiation therapy services has increased. Some health services have struggled to meet this increasing demand because of a shortage of trained personnel and expensive radiation treatment machines (<a href="./references#CD003860-bbs2-0046" title="AshD . Waiting times for cancer treatment. Clinical Oncology2000;12(3):140. [PMID 10942327] ">Ash 2000</a>; <a href="./references#CD003860-bbs2-0075" title="MackillopWJ , FuH , QuirtCF , DixonP , BrundageM , ZhouY . Waiting for radiotherapy in Ontario. International Journal of Radiation Oncology, Biology, Physics1994;30(1):221‐8. ">Mackillop 1994</a>). </p> </section> <section id="CD003860-sec-0032"> <h3 class="title" id="CD003860-sec-0032">Description of the intervention</h3> <p>Radiation following breast conserving surgery involves treatment to the breast with ionising radiation. Typically the radiation is delivered over a period of five to six weeks using a standard 2 Gy (Gray) radiation dose per fraction, in 25 to 30 treatment episodes, to a total dose of 50 to 60 Gy. </p> </section> <section id="CD003860-sec-0033"> <h3 class="title" id="CD003860-sec-0033">How the intervention might work</h3> <p>Recently there has been interest from cancer service providers in shortening the overall treatment time. One method of achieving this is to increase the size of each fraction thereby decreasing the total number of fractions required. For example, case series using 40 Gy in 15 fractions or 36 Gy in 12 fractions have been reported (<a href="./references#CD003860-bbs2-0046" title="AshD . Waiting times for cancer treatment. Clinical Oncology2000;12(3):140. [PMID 10942327] ">Ash 2000</a>; <a href="./references#CD003860-bbs2-0024" title="OlivottoIA , WeirLM , Kim‐SingC , BajdikCD , TrevisanCH , DollCM , et al. Late cosmetic results of short fractionation for breast conservation. Radiotherapy and Oncology1996;41(1):7‐13. [PMID 8961362] ">Olivotto 1996</a>). Shorter fractionation schedules have the advantages of using machine and staff time more efficiently and reducing patient inconvenience. </p> <p>Concerns have been raised, however, as to whether shorter fractionation schedules have equivalent outcomes in terms of local tumour control, breast appearance (cosmesis), late toxicity, overall survival and patient satisfaction. The concern with larger fraction sizes is based on radiobiological principles which state that the fraction size is the dominant factor in determining late side effects. The aim of conventional fractionation at 2 Gy per fraction is to decrease the rate of late tissue damage whilst aiming to maximise tumour control with acceptable acute toxicity (<a href="./references#CD003860-bbs2-0066" title="HallEJ . Radiobiology for the Radiologist. 4th Edition. Philadelphia: JB Lippincott, 1994:277. [ISBN 0 397‐51248‐1] ">Hall 1994</a>). Higher fraction size could lead to increased scarring and retraction of breast tissue as well as skin atrophy (thinning) and telangiectasia (dilated blood vessels). </p> </section> <section id="CD003860-sec-0034"> <h3 class="title" id="CD003860-sec-0034">Why it is important to do this review</h3> <p>The optimal fractionation schedule is not well‐established (<a href="./references#CD003860-bbs2-0100" title="WhelanT , MarcellusD , ClarkRM , LevineM . Adjuvant radiotherapy for early breast cancer: patterns of practice in Ontario. Canadian Medical Association Journal1993;149(9):1273‐7. ">Whelan 1993</a>) but evidence from clinical trials suggests that the results of shorter schedules may be equivalent with respect to local control and cosmesis (<a href="./references#CD003860-bbs2-0101" title="WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. ">Whelan 2002a</a>; <a href="./references#CD003860-bbs2-0105" title="YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Yarnold 1994</a>). Published trials to date have been too small to detect differences in cancer recurrence rates reliably. </p> <p>If a shorter fractionation schedule was shown to provide equivalent outcomes for women this could lead to more efficient use of radiation services and more expedient treatment for women with early breast cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003860-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003860-sec-0035"></div> <p>To assess the effect of altered radiation fraction size for women with early breast cancer who have had breast conserving surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003860-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003860-sec-0036"></div> <section id="CD003860-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003860-sec-0038"> <h4 class="title">Types of studies</h4> <p>Only randomised controlled trials were considered for inclusion. We required the comparisons to be unconfounded, that is the treatment given to the intervention and comparator groups could differ only in relation to the fractionation schedule used. Trials where the participants received adjuvant treatment in the form of chemotherapy, monoclonal antibody treatment, or hormonal therapy were eligible providing these treatments were applied equally to all study groups. Published and unpublished studies were eligible. Outcomes were not used as criteria for considering studies for inclusion in this review. </p> </section> <section id="CD003860-sec-0039"> <h4 class="title">Types of participants</h4> <p>Women with histologically confirmed early breast cancer who had undergone breast conserving surgery. Early breast cancer is defined as invasive adenocarcinoma restricted to the breast, plus or minus the local lymph nodes, which can be removed surgically (<a href="./references#CD003860-bbs2-0058" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG), DarbyS , McGaleP , CorreaC , TaylorC , ArriagadaR , ClarkeM , et al. Effect of radiotherapy after breast‐conserving surgery on 10‐year recurrence and 15‐year breast cancer death: meta‐analysis of individual patient data for 10,801 women in 17 randomised trials.. Lancet2011;378:1707‐16. ">EBCTCG 2011</a>), that is T1‐2, N0‐1, M0 (<a href="./references#CD003860-bbs2-0062" title="FlemingI , CooperJ , HensonD , HutterR , KennedyB , MurphyG , et al. AJCC Cancer Staging Manual. 5th Edition. Philadelphia: Lippincott‐Raven, 1997. ">Fleming 1997</a>). </p> <p>Surgery could include lumpectomy, wide local excision, quadrantectomy, or segmental resection; with or without axillary dissection, node sampling, or sentinel node biopsy. If a study included the relevant population as a subgroup and the outcomes relating to this group were reported separately, we included those participants eligible for this review (e.g. <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>). </p> </section> <section id="CD003860-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Postoperative radiation to the breast alone and delivered using conventional fractionation (1.8 to 2 Gy per fraction) versus postoperative radiation to the breast alone at greater than 2 Gy per fraction. The dose prescribed and the prescription point had to be clearly identified. We specified the dose in accordance with the International Commission on Radiation Units and Measurements' (ICRU 50)(<a href="./references#CD003860-bbs2-0072" title="JonesD . ICRU Report 50—Prescribing, Recording and Reporting Photon Beam Therapy. Medical Physics1994;21:833. ">Jones 1994</a>) recommendations with respect to dose, dose specification point and dose per fraction. Where possible, we converted data found in studies into this form. Partial breast irradiation was excluded because it is the subject of another Cochrane systematic review (see: <a href="./references#CD003860-bbs2-0073" title="LehmanM , HickeyBE , FrancisDP , SeeAM . Partial breast irradiation for early breast cancer. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD007077.pub2] ">Lehman 2014</a>). </p> </section> <section id="CD003860-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD003860-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003860-list-0001"> <li> <p>Local recurrence‐free survival (LR‐FS) in the ipsilateral breast (i.e. events defined as cancer detected in the same breast where the cancer had been diagnosed). </p> </li> <li> <p>Appearance or cosmesis (objective and subjective) of the treated breast.</p> </li> </ol> </p> </section> <section id="CD003860-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003860-list-0002"> <li> <p>Overall survival (OS; time from date of randomisation to death from any cause, or number of deaths from any cause). </p> </li> <li> <p>Toxicity (including acute and late effects of radiation therapy and chemotherapy‐related toxicity); we used individual protocol‐based definitions. </p> </li> <li> <p>Breast cancer‐specific survival (BC‐SS; events were: death due to breast cancer).</p> </li> <li> <p>Relapse‐free survival (RFS; events included local recurrence, loco‐regional recurrence, distant metastasis and death). </p> </li> <li> <p>Mastectomy rate (salvage following local recurrence or unacceptable toxicity).</p> </li> <li> <p>Quality of life (trial‐specific instruments).</p> </li> <li> <p>Costs (to women and health services).</p> </li> </ol> </p> </section> </section> </section> <section id="CD003860-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>Searches were not limited by language or date.</p> <section id="CD003860-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ol id="CD003860-list-0003"> <li> <p>Cochrane Breast Cancer Specialised Register (23 May 2015). The details of search strategies used by the Group for the identification of studies and the procedure used to code references are outlined in their module (<a href="./references#CD003860-bbs2-0050" title="Wilcken N, Goodwin A, Alderman A, Barrett J, Bulsara M, Clarke M et al for Cochrane Breast Cancer. In: The Cochrane Library, 2016, Issue 6. Chichester: John Wiley &amp; Sons, Ltd. Updated monthly. ">Breast Cancer Group 2016</a>). We extracted studies coded as 'early' and 'radiotherapy' and 'dose intensity' in the Specialised Register for consideration; </p> </li> <li> <p>CENTRAL (<i>The Cochrane Library</i> 2015, Issue 4). See <a href="./appendices#CD003860-sec-0159">Appendix 1</a> for search strings; </p> </li> <li> <p>MEDLINE (OVID) (1966 to May 2015). See <a href="./appendices#CD003860-sec-0160">Appendix 2</a> for search strings; </p> </li> <li> <p>EMBASE (OVID) (1980 to May 2015). See <a href="./appendices#CD003860-sec-0161">Appendix 3</a> for search strings; </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for the period 10 June 2010 until May 2015. See <a href="./appendices#CD003860-sec-0162">Appendix 4</a>; </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) on 16 April 2015. See <a href="./appendices#CD003860-sec-0163">Appendix 5</a>; </p> </li> <li> <p>Grey literature (<a href="http://www.opengrey.org" target="_blank">opengrey.org</a>) on 06 May 2015. See <a href="./appendices#CD003860-sec-0164">Appendix 6</a>. </p> </li> </ol> </p> </section> <section id="CD003860-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We handsearched the following conference proceedings:</p> <p> <ol id="CD003860-list-0004"> <li> <p>American Society of Oncology: 1995‐2010;</p> </li> <li> <p>European Society for Therapeutic Radiation Oncology: 1990, 1993, 2000‐2010, 2012;</p> </li> <li> <p>American Society for Therapeutic Radiation: 2011, 2012, 2014;</p> </li> <li> <p>We searched reference lists of published studies and review articles.</p> </li> </ol> </p> </section> </section> <section id="CD003860-sec-0047"> <h3 class="title" id="CD003860-sec-0047">Data collection and analysis</h3> <section id="CD003860-sec-0048"> <h4 class="title">Selection of studies</h4> <p>In the previous versions and 2015 review update, two or more authors checked the titles and abstracts retrieved by the searches (previous versions: four authors; 2015 review update: BH and MJ). Two authors (BH and MJ) independently assessed the full text of all studies we thought relevant to the review with differences being resolved by discussion. </p> </section> <section id="CD003860-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two authors (BH and ML) performed data extraction independently, with disagreements being resolved by discussion. We entered data into Review Manager 5.3 (<a href="./references#CD003860-bbs2-0087" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) for analysis. Where data were limited, we requested further information from the authors of the original studies. We received data from the authors of <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>. Data for local recurrence events was derived from percentages (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) where raw numbers were not available (we assumed the denominators used were the numbers in each arm of the trial). Where there were two experimental arms using altered fraction size (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>), we combined the number of events and denominators to form a single experimental arm. </p> <p>We calculated the log rank statistic (O‐E) and its variance for time‐to‐event outcomes using an Excel spreadsheet developed by Matthew Sydes (Cancer Division) in collaboration with the Meta‐analysis Group of the MRC Clinical Trials Unit, London (<a href="./references#CD003860-bbs2-0096" title="TierneyJ , StewartL , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16):1‐16. ">Sydes 2007</a>). For <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, to derive O‐E and variance for: LR‐FS, OS, BC‐SS and RFS, we used Method four (where HR, number of events in each arm and the randomisation is 1:1). We used Method four to derive O‐E and variance for OS (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). We used Method six to derive O‐E and variance for LR‐FS (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>) (where HR and total number of events are available and randomisation need not be 1:1), OS, RFS and BC‐SS (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>). We used Method eleven to derive LR‐FS and R‐FS (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>; data extracted from the curve where numbers at risk are available). Method seven was used to derive O‐E and variance for BC‐SS (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>; where P value, events in each arm available and randomisation ratio is 1:1). </p> <p>We reported cosmetic outcome using a four‐point scale (see additional <a href="#CD003860-tbl-0002">Table 1</a>: <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). This was dichotomised and those who had fair/poor results were counted as having events. For <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, we derived figures from percentages given in the text. </p> <div class="table" id="CD003860-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">EORTC Cosmetic Rating System</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global cosmetic</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference or excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small difference or good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate difference or fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large difference or poor</p> </td> </tr> </tbody> </table> </div> <p>Acute toxicity: two different five‐point scales were used (<a href="./references#CD003860-bbs2-0052" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>; <a href="./references#CD003860-bbs2-0080" title="US Department of Health and Human Services, National Institute of Health, National Cancer Institute. Common toxicity criteria for adverse effects (CTCAE). evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 08/08/15), issue Version 4.0. ">NCI</a>); any woman who had Grade II toxicity or more was scored as having an event. Although they are both five‐point scales, the <a href="./references#CD003860-bbs2-0080" title="US Department of Health and Human Services, National Institute of Health, National Cancer Institute. Common toxicity criteria for adverse effects (CTCAE). evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 08/08/15), issue Version 4.0. ">NCI</a> does not always use all five grades. After examining the descriptions for each grade in the two different scales, we chose to report any women with Grade 2 toxicity or more as having an event (see <a href="#CD003860-tbl-0003">Table 2</a> and <a href="#CD003860-tbl-0004">Table 3</a>). </p> <div class="table" id="CD003860-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RTOG CTCAE acute skin toxicity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No visible change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faint/dull erythema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tender/bright erythema +/‐ dry desquamation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patchy moist desquamation, moderate erythema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confluent moist desquamation, pitting oedema</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003860-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTCAE Version 4.0</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild; asymptomatic or mild<br/> symptoms; clinical or diagnostic<br/> observations only; intervention not<br/> indicated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate; minimal, local or<br/> noninvasive intervention indicated;<br/> limiting age‐appropriate<br/> instrumental ADL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe or medically significant but<br/> not immediately life‐threatening;<br/> hospitalisation or prolongation of<br/> hospitalisation indicated; disabling;<br/> limiting self‐care ADL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life‐threatening consequences;<br/> urgent intervention indicated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death related to adverse event</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADL: activities of daily living</p> </div> </div> <p>Late radiation therapy (RT) toxicity (telangiectasia, breast oedema, subcutaneous toxicity): any woman who had Grade 2 toxicity or more was scored as having an event. </p> <p>Rib fractures: we reported radiologically confirmed rib fractures (excluding those related to metastases and trauma). </p> <p>We reported ischaemic heart disease for those women with left‐sided tumours, and those with pre‐existing heart disease were excluded. </p> <p>Pulmonary fibrosis was confirmed radiologically.</p> <p>We converted the radiation doses to the equivalent dose in 2 Gy fractions (EQD<sup>2</sup> ) (<a href="./references#CD003860-bbs2-0074" title="MaciejewskiB , TaylorJM , WithersHR . Alpha/beta value and the importance of size of dose per fraction for late complications of the supraglottic larynx. Radiotherapy and Oncology1986;7(4):323‐6. ">Maciejewski 1986</a>; <a href="./references#CD003860-bbs2-0104" title="WithersHR , ThamesHDJr , PetersLJ . A new isoeffect curve for change in dose per fraction. Radiotherapy and Oncology1983;1(2):187‐91. ">Withers 1983</a>), using the formula: EQD<sup>2</sup> = D (d + alpha/beta/2 + alpha/beta), where D = total dose, d = dose per fraction and alpha/beta = 4 Gy (<a href="./references#CD003860-bbs2-0084" title="OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long‐term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. ">Owen 2006b</a>; see <a href="#CD003860-tbl-0005">Table 4</a>). This was to facilitate comparison of radiation doses given at differing dose per fraction. We converted brachytherapy (radiation sources applied directly to the body) to the biological equivalent dose (BED) using the method of <a href="./references#CD003860-bbs2-0095" title="StittJA , FowlerJF , ThomadsenBR , BuchlerDA , PaliwalBP , KinsellaTJ . High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison System 1: Clinical and radiobiological considerations. International Journal of Radiation Oncology, Biology, Physics1992;24(2):335‐48. ">Stitt 1992</a>. </p> <div class="table" id="CD003860-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Conversion of altered fractionation regimen to EQD2 </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fractions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQD<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.9 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control arm dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> <p><a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.5 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> </p> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> <br/> <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> </p> <p><a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.90</p> </td> </tr> </tbody> </table> </div> <p>We reported the P values for any difference in the mean score (measured at baseline and six months) for patient‐reported quality of life measures scored using FACT‐B (<a href="./references#CD003860-bbs2-0049" title="BradyMJ , CeliaDF , MoF , BonomiAE , TulskyDS , LloydSR , et al. Reliability and validity of the Functional Assessment of Cancer Therapy‐Related Breast quality‐of‐life instrument. Journal of Clinical Oncology1997;15(3):974‐86. ">Brady 1997</a>; <a href="./references#CD003860-bbs2-0099" title="WebsterK , CelieD , YostK . The Functional Assessement of Chronic Illness Therapy (FACIT) Measurement System: properties, applications and interpretation. Health Quality of Life Outcomes2003;1:79. ">Webster 2003</a>). </p> </section> <section id="CD003860-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BH, ML) categorised the risk of bias of each eligible study using the system outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003860-bbs2-0069" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). DF resolved any discrepancies that arose. BH constructed and ML reviewed 'Risk of bias' tables for the included studies, with any discrepancies resolved by discussion. We constructed a 'Risk of bias' graph with review authors' judgements about each methodological quality item (presented as percentages across all included studies). We separated assessment of risk of bias into subjective (e.g. cosmesis) and objective outcomes (e.g. LR‐FS). </p> <p>We planned sensitivity analysis on the basis of study quality, which was to be performed with and without trials of low quality to assess the effect of quality on the results. </p> </section> <section id="CD003860-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We presented results so that a result less than one favoured the experimental arm (hypofractionation). Summary statistics for dichotomous measures were presented as risk ratios (RR) with 95% confidence intervals (CI) (<a href="./references#CD003860-bbs2-0054" title="DeeksJJ , HigginsJPT , AltmanDG . Analysing and presenting results. In: AldersonP , GreenS , HigginsJPT editor(s). Cochrane Reviewers' Handbook 4.2.2. Vol. The Cochrane Library 2004, Issue 1, Chichester, UK: John Wiley &amp; Sons Ltd, 2003. ">Deeks 2003</a>). Summary statistics for continuous variables were presented as mean differences (MD), where possible. We used Mantel‐Haenszel methods to calculate pooled risk ratios (<a href="./references#CD003860-bbs2-0065" title="GreenlandS , RobbinsJ . Estimation of a common effect parameter from sparse follow‐up data. Biometrics1985;41(1):55‐68. ">Greenland 1985</a>; <a href="./references#CD003860-bbs2-0076" title="MantelM , HaenszelWH . Statistical aspects of the analysis of data for retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). Where possible, we used the HR to present time‐to‐event data for the endpoints of LR‐FS, OS, RFS, with 95% CI. </p> <p>We deemed that a HR equal to or less than 0.75 and equal to or greater than 1.25 was clinically meaningful. In the absence of clear direction in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003860-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>), we made a pragmatic decision based on our expert opinions as clinicians and used the Federal Drug Administration (FDA) method (<a href="./references#CD003860-bbs2-0042" title="EPC Work Group. Assessing equivalence and non‐inferiority. effectivehealthcare.ahrq.gov/ehc/products/365/1154/Assessing‐Equivalence‐and‐Noninferiority_FinalReport_20120613.pdf (accessed 28/03/16). ">AHRQ 2011</a>) to choose (post‐hoc) the minimal clinically important difference (MID), using a figure 50% of the difference tested for in a randomised study (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>). <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> was powered to detect a 5% difference in local relapse, so we chose 2.5% for our MID. We considered that for LR‐FS, BC‐SS and OS, a reasonable MID was 2.5%, as this is less than half the effect size sought in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> (5%), and was chosen to be deliberately conservative. Therefore if the upper limit of the confidence interval indicated the intervention was less then 2.5% worse than the control, we concluded non‐inferiority. </p> </section> <section id="CD003860-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Because the unit of analysis was the participant, we did not have any unit of analysis issues. </p> </section> <section id="CD003860-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the study authors for any missing data.</p> </section> <section id="CD003860-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity both visually and statistically using the Chi<sup>2</sup> test (<a href="./references#CD003860-bbs2-0045" title="AltmanDG . Practical statistics for medical research. London: Chapman and Hall, 1992. ">Altman 1992</a>; <a href="./references#CD003860-bbs2-0098" title="WalkerAM , Martin‐MorenoJM , ArtalejoFR . Odd man out: a graphical approach to meta‐analysis. American Journal of Public Health1988;78(8):961‐6. ">Walker 1988</a>) and the Higgins I<sup>2</sup> statistic (<a href="./references#CD003860-bbs2-0067" title="HIgginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>; <a href="./references#CD003860-bbs2-0068" title="HIgginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). We acknowledge that with few studies the statistical power to detect heterogeneity is low. </p> </section> <section id="CD003860-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to assess for publication bias where we had five or more studies.</p> </section> <section id="CD003860-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We extracted data from the trials according to the intention‐to‐treat (ITT) principle where possible and determined a weighted average treatment effect using the fixed‐effect model to combine results (<a href="./references#CD003860-bbs2-0076" title="MantelM , HaenszelWH . Statistical aspects of the analysis of data for retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>) in RevMan 5.3 (<a href="./references#CD003860-bbs2-0087" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Where it was possible to derive the log rank statistic (O‐E) and its variance from the presented data, we used Peto's method to estimate the pooled hazard ratio (HR). Our comparison of interest was altered fraction size (hypofractionation) versus conventional fractionation, so when analysing the trials we combined the two different 'fractionation dose' altered arms of the <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> trials as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003860-bbs2-0055" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). In the future, if more information becomes available, separate analysis may be possible to investigate a dose effect for different fractionation schedules. </p> <section id="CD003860-sec-0057"> <h5 class="title">Acute radiation toxicity</h5> <p> <ol id="CD003860-list-0005"> <li> <p>Acute skin toxicity was reported for <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>. </p> </li> </ol> </p> </section> <section id="CD003860-sec-0058"> <h5 class="title">Late radiation toxicity</h5> <p> <ol id="CD003860-list-0006"> <li> <p>Late skin toxicity (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) was assessed at five and ten years using a five‐point scale (<a href="./references#CD003860-bbs2-0103" title="WinchesterDP , CoxJD . Standards for breast‐conservation treatment. CA: Cancer Journal for Clinicians1992;42(3):134‐62. ">Winchester 1992</a>) (see additional <a href="#CD003860-tbl-0006">Table 5</a>) and analysed as a dichotomous outcome using RR. The results were dichotomised into: none or mild versus moderate, marked or severe. We reported the women who had ≥ Grade II toxicity for each arm (percentages given in text converted to numbers). </p> </li> <li> <p>Ischaemic heart disease for women with left‐sided tumours without pre‐existing heart disease (at median follow‐up 9.3 to 9.9 years) was reported in full (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>). </p> </li> <li> <p>Rib fractures, those confirmed and excluding those secondary to trauma or metastatic disease (at median follow‐up 9.3 to 9.9 years) were reported in full (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>). </p> </li> <li> <p>Induration (fibrosis) and subcutaneous toxicity:</p> </li> </ol> </p> <div class="table" id="CD003860-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC late radiation morbidity scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slight toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe toxicity</p> </td> </tr> </tbody> </table> </div> <p>We assumed that induration and subcutaneous toxicity, reported by or at five years by <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> respectively and at ten years (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) represented the same outcome and could, therefore, be combined for analysis. <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> used the RTOG/EORTC five‐point late radiation morbidity scale, with the women assessed by a trained nurse (<a href="./references#CD003860-bbs2-0103" title="WinchesterDP , CoxJD . Standards for breast‐conservation treatment. CA: Cancer Journal for Clinicians1992;42(3):134‐62. ">Winchester 1992</a>) (see Additional <a href="#CD003860-tbl-0006">Table 5</a>). <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> used a four‐point trial‐specific scale (see Additional <a href="#CD003860-tbl-0007">Table 6</a>) and the outcome was assessed by physicians. In <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, the women were assessed by physicians using a four‐point scale (see <a href="#CD003860-tbl-0008">Table 7</a>) and the results dichotomised: those women with Grade II toxicity or above had an event recorded. The results were dichotomised in the <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> report but reported in full in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. In order to combine the results, we dichotomised the <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> results into two groups: those with nil or slight late radiation toxicity, and those who had any greater toxicity; that is the women who had scores of two or more were counted as having toxicity. No participant in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> had severe (Grade 4) toxicity. </p> <div class="table" id="CD003860-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Induration scale (Owen 2006a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003860-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">START A &amp; B Late RT toxicity scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"none"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"a little"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"quite a bit"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"very much"</p> </td> </tr> </tbody> </table> </div> <p>Marked or any change in breast appearance: results were dichotomised in the report (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>). </p> <p>If sufficient data becomes available in future updates we will use recommended methods to collect and combine the data. We will use the mean difference method unless trials have reported results on different scales, in which case we will use a standardised mean difference to summarise data (<a href="./references#CD003860-bbs2-0055" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD003860-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>Using the GRADE approach, we created a 'Summary of findings' table based on the following outcomes. </p> <p> <ol id="CD003860-list-0007"> <li> <p>Local recurrence‐free survival</p> </li> <li> <p>Cosmesis</p> </li> <li> <p>Overall survival (called mortality in Summary of Findings Table)</p> </li> <li> <p>Toxicity (late sub‐cutaneous toxicity/fibrosis)</p> </li> <li> <p>Breast cancer‐specific survival</p> </li> <li> <p>Relapse‐free survival</p> </li> <li> <p>Mastectomy rate</p> </li> </ol> </p> <p>Refer to <a href="./full#CD003860-tbl-0001">summary of findings Table for the main comparison</a>. To calculate the absolute risk for the control group for time‐to‐event outcomes in the 'Summary of Findings' table, we estimated the event rate at a specific time point (10 years for LR‐FS, Mortality, BC‐SS, and RFS) from the Kaplan‐Meier curves or reported event rates in the included studies. These estimated values were entered in <a href="./references#CD003860-bbs2-0064" title="GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org. ">GRADEproGDT</a> software and the corresponding absolute risks for the intervention group at 10 years were automatically populated by the software. </p> </section> </section> <section id="CD003860-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis based on length of follow‐up (4.2 years versus approximately 10 years) and by dose (experimental arm &lt; 50 Gy versus ≥ 50 Gy). In the two studies with two intervention arms where the doses were both less than 50 Gy and equal to or greater than 50 Gy (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>) and the results were not reported by dose stratum, we were not able to include them in the subgroup analysis. </p> <p>If sufficient data become available in future updates we may perform subgroup analyses to investigate whether the effects of different radiation fraction schedules differ depending on nodal status, margin status, hormone receptor status, and tumour stage or other factors which may become relevant in the future. If heterogeneity is detected we will first check the data to ensure accuracy, in the knowledge that with small study numbers, the power of statistical testing for heterogeneity is low. </p> </section> <section id="CD003860-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We did sensitivity analysis based on risk of bias, excluding studies deemed at high risk of bias (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003860-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003860-sec-0062"></div> <section id="CD003860-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD003860-sec-0064"> <h4 class="title">Results of the search</h4> <p>For this update of the review, we screened a total of 2627 abstracts, and considered 53 papers in full for eligibility. We excluded 25 full‐text publications (see <a href="./references#CD003860-sec-0175" title="">Characteristics of excluded studies</a>) and identified 28 new reports. Twelve reports referred to five new included studies (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>). Eight reports related to three previously included studies (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). Eight reports referred to five ongoing studies (<a href="./references#CD003860-bbs2-0035" title="AdriaenssensN , DeRidderM , LievensP , VanParijsH , VanhoeijM , MiedemaG , et al. Scapula alata in early breast cancer patients enrolled in a randomized controlled trial of post‐surgery short‐course image‐guided radiotherapy. World Journal of Surgery2012;10:86. AdriaenssensN , Vinh‐HungV , MiedemaG , VersmessenH , LamoteJ , VanhoeijM , et al. Early contralateral shoulder‐arm morbidity in breast cancer patients enrolled in a randomized trial of post‐surgery radiation therapy. Breast Cancer (Auckland)2012;6:79‐93. NCT00459628 . Randomized trial comparing conventional vs short‐course reduced volume conformal post‐surgery radiation treatment in women with stage I or II breast cancer. clinicaltrials.gov/ct2/show/NCT00459628?id=NCT00459628&amp;rank=1 (accessed 30/09/15). VanParijsH , MiedemaG , Vinh‐HungV , VerbanckS , AdriaenssensN , KerkhoveD , et al. Short course radiotherapy with simultaneous integrated boost for stage I‐II breast cancer, early toxicities of a randomized clinical trial. Radiotherapy and Oncology2012;7:80. VersmessenH , Vinh‐HungV , VanParijsH , MiedemaG , VoordeckersM , AdriaenssensN , et al. Health‐related quality of life in survivors of stage I‐II breast cancer: randomized trial of post‐operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer2012;12:495. ">NCT00459628</a>; <a href="./references#CD003860-bbs2-0037" title="NCT01266642 . Randomized trial of hypofractionated whole breast irradiation versus conventionally fractionated whole breast irradiation for ductal carcinoma in situ and early invasive breast cancer. clinicaltrials.gov/ct2/show/NCT01266642 (accessed 13 April 2015). ">NCT01266642</a>; <a href="./references#CD003860-bbs2-0036" title="NCT00909818 . Hypofractionated versus standard fractionated whole breast irradiation to node‐negative breast cancer patients. clinicaltrials.gov/show/NCT00909818 (accessed 10 June 2010). ">NCT00909818</a>; <a href="./references#CD003860-bbs2-0038" title="NCT01349322 . A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early‐stage breast cancer. clinicaltrials.gov/ct2/show/NCT01349322 (accessed 16 April 2015). ">NCT01349322</a>; <a href="./references#CD003860-bbs2-0039" title="NCT01413269 . Phase 3 open‐labeled randomized clinical study of comparing hypofractionated and conventional radiotherapy for breast cancer patients after breast conservative surgery. clinicaltrials.gov/ct2/show/NCT01413269 (accessed 16 April 2015). ">NCT01413269</a>). See <a href="#CD003860-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003860-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for updated review" data-id="CD003860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for updated review</p> </div> </div> </div> <p>When combining studies from the previous review and this update, 39 reports that met the inclusion criteria related to nine separate studies (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). All of the trials had published their results at different times with different periods of follow‐up. We used the most recent publication as the source for the review, supplementing this with information from earlier reports if necessary. Thus, for the <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> trial the primary source is <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>, with 10 other records found for this trial. The primary source for the <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> was <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, with six other reports found. For <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>, there were seven records with one publication (Sumo 2008) that was also relevant to <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> had two reports, <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> contained seven records, <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> had two records and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> had one record while <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> were reported only in one report each in abstract form. </p> </section> <section id="CD003860-sec-0065"> <h4 class="title">Included studies</h4> <p>The nine randomised trials included in this current version of the review involved a total of 8228 women. </p> <section id="CD003860-sec-0066"> <h5 class="title">Participants</h5> <p>The women studied in this review were mostly women with early breast cancer (6829/7553 (90.4%)) and 4580 out of 8010 (57%) women were aged 50 or more where reported (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). Seventy‐two out of 287 (25%) of the women in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> and 59 women in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> had Stage 0 early breast cancer or ductal carcinoma in situ (DCIS): in total, 131/8228 (0.15%) women had DCIS. Further, 6701/6701 (100%) of the women studied in this review had negative pathological margins, where reported (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). Most tumours (3916/6600 (59%)) were 2 cm or less in size, where size was reported (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) and 4457/4853 (91%) were 3 cm or less in size (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>). Women with T3 tumours (that is tumour size greater than 5 cm) were eligible for the <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> studies. They comprised 1.6% (22/1410) of the women studied in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>. T stage was not reported in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, but 15% (702/4451) of women had tumours larger than 3 cm. Most women 5040/6135 (82%) studied in this review, had small to medium breasts (where breast size was reported) (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>), in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> (those with cup size D or less). Most women (5332/7824 (68%)) studied in this review were node negative where reported (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) and most women (7675/8188 (93.7%)) studied were treated with breast conserving surgery. <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> included 131 women with early breast cancer, we included the 47 women treated with breast conserving surgery, where the results were reported separately. </p> </section> <section id="CD003860-sec-0067"> <h5 class="title">Interventions</h5> <section id="CD003860-sec-0068"> <h6 class="title">Radiation therapy dose</h6> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> compared two different fractionation regimens (42.5 Gy in 16 fractions and 50 Gy in 25 fractions). <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> compared three fractionation regimens (39 Gy in 13 fractions, 42.9 Gy in 13 fractions, and 50 Gy in 25 fractions). <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> compared three regimens (41.6 Gy in 13 fractions, 39 Gy in 13 fractions and 50 Gy in 25 fractions). <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> compared two fractionation regimens (40 Gy in 15 fractions and 50 Gy in 25 fractions). <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> compared three regimens: 30 Gy in five fractions, 28.5 Gy in five fractions and 50 Gy in 25 fractions. <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> compared 30 Gy in 5 fractions versus 50 Gy in 25 fractions. See <a href="#CD003860-tbl-0005">Table 4</a> for comparison of BED and EQD<sub>2</sub>. </p> <p>The RT delivered in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> used techniques to: </p> <p> <ol id="CD003860-list-0008"> <li> <p>improve dose heterogeneity (wedging, 3D compensation or intensity modulated RT (IMRT)); they specified that dose received did not exceed 108% of prescribed dose; </p> </li> <li> <p>reduce lung dose (respiratory gating);</p> </li> <li> <p>improve accuracy (CT planning).</p> </li> </ol> </p> </section> <section id="CD003860-sec-0069"> <h6 class="title">Boost to tumour bed</h6> <p>Overall, 3454/7715 (44.7%) of the women studied received a boost (an extra dose delivered to the tumour bed) (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>). In the experimental arm, 1390/3581 (38.8%) of women received a boost and in the control arm 972/2772 (35%) received a boost (data excludes <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>, where boost was not reported by study arm; see <a href="#CD003860-tbl-0009">Table 8</a>). </p> <div class="table" id="CD003860-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Boost for women treated with breast conservation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>STUDY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast conservation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Boost experimental arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Boost control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6 Gy/13 fractions arm: 391/750 (61%)</p> <p>39 Gy/13 fractions arm: 380/737 (60.5%)</p> <p>Total number with boost: 771/1269 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381/631 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1152/1900 (61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446/1018 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422/1020</p> <p>(41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868/2038</p> <p>(43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>―</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>―</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1051/1410 (75%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/729 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1234 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41/47 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/30 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138/138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149/149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/287 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Total number boosted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454/7715 (44%)</p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>: 1051/1410 (75%) were treated with a boost of 14 Gy at 90% in seven fractions. The authors did not report how many women in each arm received a boost. For women with negative margins, if the clinician felt it was appropriate, there was a sub‐randomisation to boost or no boost from January 1986 to May 1994. After this, all 687 participants were offered an elective boost (see additional <a href="#CD003860-tbl-0009">Table 8</a>). The boost dose delivered was not reported in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>. The planning target volume (PTV) for the boost was clearly defined in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>. <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>: for women treated with breast conservation, 771/1269 (61%) of women in the experimental arm and 381/631 (60%) of women in the control arm received a boost of 10 Gy in five fractions using electrons. In total, 1152/1900 (61%) received a boost. Each participating department specified in advance whether participants enrolled from that site would receive radiotherapy boost (see additional <a href="#CD003860-tbl-0009">Table 8</a>). <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>: for women treated with breast conservation, 446/1018 (44%) and 422/1020 (41%) received a 10 Gy on five fraction boost using electrons. In total, 868/2038 (43%) received a boost. Each participating department specified in advance whether participants enrolled from that site would receive radiotherapy boost (see additional <a href="#CD003860-tbl-0009">Table 8</a>). 15/30 women in <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> (all the conventional arm) received a boost (see <a href="#CD003860-tbl-0009">Table 8</a>). </p> <p>No women in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> or <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> were treated with boosts. </p> </section> <section id="CD003860-sec-0070"> <h6 class="title">Regional nodal irradiation</h6> <p>318/2236 (1.3%) of women in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and 161/2215 (7%) women in <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> were treated with regional nodal RT. </p> </section> <section id="CD003860-sec-0071"> <h6 class="title">Co‐interventions</h6> <p>In total, 5566/7513 (74%) women received hormonal manipulation (mostly tamoxifen) and 1709/8188 (21%) received chemotherapy. No women in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> received adjuvant chemotherapy, 704 received tamoxifen and 102 an aromatase inhibitor. In total, 196/1410 women received chemotherapy and 1074/1410 received tamoxifen (numbers not given by study arm; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>). All (47/47) the women in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> received chemotherapy. In <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> 1758/2236 women received tamoxifen and 793/2236 women received chemotherapy and in <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> 1928/2215 women received tamoxifen and 491/2215 women received chemotherapy. <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> treated 20/30 women with chemotherapy +/‐ hormonal therapy (not detailed by study arm) and 17/30 women received chemotherapy. One hundred and thirty‐six out of 1234 women in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> received chemotherapy, 28 out of 287 women in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> received neoadjuvant chemotherapy and in total, 28/7800 (0.3%) of women received neoadjuvant chemotherapy. </p> <p>No co‐interventions were reported in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>. </p> </section> <section id="CD003860-sec-0072"> <h6 class="title">Quality assurance for radiation therapy</h6> <p>Both <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> had a rigorous quality assurance programme to ensure the RT delivered was adherent to protocol. In <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> there was no trial‐specific quality assurance, other than institutional peer review process of radiation therapy plans. </p> </section> </section> <section id="CD003860-sec-0073"> <h5 class="title">Outcomes</h5> <section id="CD003860-sec-0074"> <h6 class="title">Local recurrence‐free survival</h6> <p>LR‐FS was reported at three and a half years (<a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>) and ten years or more follow‐up in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. </p> </section> <section id="CD003860-sec-0075"> <h6 class="title">Cosmesis</h6> <p>Participant‐reported cosmetic outcome was reported in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>. Trained clinical trials nurses in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> and a blinded physician panel in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> assessed global cosmetic outcome using the four‐point European Organisation for Research and Treatment of Cancer (EORTC) Cosmetic Rating System (<a href="#CD003860-tbl-0002">Table 1</a>). Of the women in the trial, 1220/1234 (98.8%) had baseline cosmetic assessment. Cosmetic outcome was assessed in the 735/1220 women with five years' follow‐up at the time of assessment (<a href="#CD003860-tbl-0009">Table 8</a>). Cosmetic assessment was done for 1220 women at baseline and complete cosmetic data was reported for 735 women at five years (the time of interest for the outcome). We have no indication that these women were different to the remainder of those randomised. Triallists used a four‐point scale (<a href="./references#CD003860-bbs2-0040" title="AaronsonNK , BartelinkH , VanDongenJA , VanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgical Oncology1988;14(2):133‐40. ">Aaronson 1988</a>) and the results were dichotomised as good or excellent versus poor or fair (<a href="#CD003860-tbl-0002">Table 1</a>). The study reported these results as percentages at three and five years with the total number of women available for evaluation at each time period; as we did not know the numbers in each arm, we were unable to derive figures from these data. In <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> and <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>, the same four‐point scale was used to assess cosmesis, by an observer blinded to treatment arm (<a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>) and the results were dichotomised as in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. </p> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> reported breast cosmesis (median follow‐up of 9.7 years, maximum 15 years) using a four‐point scale (<a href="#CD003860-tbl-0010">Table 9</a>). A total of 806 women (see <a href="#CD003860-sec-0063">Description of studies</a>) were assessed and the results were reported for a dichotomous outcome in the report. We have no evidence that these women were substantially different to the remainder of women in the trial: the reasons that women were not followed up were not related to which arm they were randomised to and were not related to whether they had local relapse or late normal tissue side‐effects from treatment. Quote: "Reasons for non‐availability were explored, and no evidence was observed that this was associated with either the fractionation schedule or to the probability of experiencing future normal tissue event or local relapse (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>)." The clinical assessment results were dichotomised in the report into fair or poor versus good or excellent (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>). </p> <div class="table" id="CD003860-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Cosmesis scale (Owen 2006a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast Cosmesis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> </tr> </tbody> </table> </div> <p>Late change in breast appearance (assessed by blinded observers) was reported in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and will be reported in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> when the follow‐up is longer. Late change in breast appearance (photographic) was assessed in the 1055 (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>) and 923 (<a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) women who had both a photo at baseline and a follow‐up photo (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>). Not all participants had a photo at five years. Those with photos at two and five years were combined when reported, and the authors did not report how many had five‐year follow‐up. We have no evidence that these women were substantially different to the remainder of women in the trial. Quote: "There were no associations between score for change in breast appearance (photographic) at two years or patient demographic or treatment characteristics and whether or not the participant had a five‐year assessment (data not shown)". </p> <p>The primary outcome measure in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> was late change in breast appearance, which was assessed in the 1202 women who had photographs available at baseline and at least a single follow‐up. Pairs of photographs were available as follows: 1128 at year one, 1004 at year two, 525 at three years, 472 at four years, 765 at five years and 141 at 10 years, i.e. photographic follow‐up was reported for 63% of women at five years, and 11% at 10 years. </p> </section> <section id="CD003860-sec-0076"> <h6 class="title">Overall survival</h6> <p>Overall survival was reported at ten years or more in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. </p> </section> <section id="CD003860-sec-0077"> <h6 class="title">Acute skin radiation therapy toxicity</h6> <p>This was assessed using the RTOG CTCAE scoring system, a five‐point scale (<a href="./references#CD003860-bbs2-0052" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>) in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> (see <a href="#CD003860-tbl-0003">Table 2</a>). Acute toxicity was assessed in <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> using NCI CTC version 4.0 (<a href="./references#CD003860-bbs2-0080" title="US Department of Health and Human Services, National Institute of Health, National Cancer Institute. Common toxicity criteria for adverse effects (CTCAE). evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 08/08/15), issue Version 4.0. ">NCI</a>; see <a href="#CD003860-tbl-0004">Table 3</a>). Those women who experienced extensive moist desquamation were reported in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> (not reported by study arm). </p> </section> <section id="CD003860-sec-0078"> <h6 class="title">Late radiation therapy toxicity</h6> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> reported late RT toxicity (un‐blinded physician assessment). Breast pain, oedema, subcutaneous fibrosis (induration), hyperpigmentation and telangiectasia were reported in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> using RTOG CTCAE (<a href="./references#CD003860-bbs2-0052" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>). Late RT toxicity was assessed in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> using LENT‐SOMA. Physicians (<a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>) and trained nurses (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) assessed late radiation toxicity using the five‐point Radiation Oncology Group/ EORTC late radiation morbidity scale (<a href="./references#CD003860-bbs2-0103" title="WinchesterDP , CoxJD . Standards for breast‐conservation treatment. CA: Cancer Journal for Clinicians1992;42(3):134‐62. ">Winchester 1992</a>) to report skin toxicity (<a href="#CD003860-tbl-0006">Table 5</a>). <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> reported late RT toxicity: breast shrinkage, telangiectasia and breast oedema was assessed annually (by physicians) in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> using a four‐point scale. Any women with Grade II toxicity or above were regarded as having an event. </p> </section> <section id="CD003860-sec-0079"> <h6 class="title">Breast cancer‐specific survival</h6> <p>BC‐SS was reported at ten years or more in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. </p> </section> <section id="CD003860-sec-0080"> <h6 class="title">Relapse‐free survival</h6> <p>RFS was reported at five years (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) and at ten years in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. </p> </section> <section id="CD003860-sec-0081"> <h6 class="title">Mastectomy rate</h6> <p>Mastectomy rates were not reported.</p> </section> <section id="CD003860-sec-0082"> <h6 class="title">Quality of life</h6> <p>Quality of life was reported separately for 1129/2236 women in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and 1079/2215 women in <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. Centres either opted in or out of participating in the quality‐of‐life data collection, but the authors report that there was no difference in terms of RT planning or delivery between centres opting to participate in the quality‐of‐life data collection or not. <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> enrolled 2208 women in the quality‐of‐life assessments. The EORTC general cancer quality‐of‐life scale (EORTC QLQ‐C30; <a href="./references#CD003860-bbs2-0041" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. National Journal of Cancer Institute1993;85(5):365‐76. ">Aaronson 1993</a>), breast cancer module (BR23; <a href="./references#CD003860-bbs2-0093" title="SprangersMA , GroenvoldM , ArrarasJI , FranklinJ , teVeldeA , MullerM , et al. The European Organization for Research and Treatment of Cancer breast cancer‐specific quality‐of‐life questionnaire module: first results from a three‐country field study. Journal of Clinical Oncology1996;14(10):2756‐68. ">Sprangers 1996</a>), the Body Image Scale (BIS; <a href="./references#CD003860-bbs2-0071" title="HopwoodP , FletcherI , LeeA , Al GhazalS . A body image scale for use with cancer patients. European Journal of Cancer2001;37:189‐97. ">Hopwood 2001</a>) and the Hospital Anxiety and Depression Scale (HADS; <a href="./references#CD003860-bbs2-0106" title="ZigmondAS , SnaithRP . The hospital anxiety and depression scale. Acta Psychiatry Scandinavia1983;67:361‐70. ">Zigmond 1983</a>) were used to evaluate quality of life. The initial publication describes the quality of life in the overall cohort of participants, and was performed prior to breaking the randomisation code. EORTC QLQ‐C30 (<a href="./references#CD003860-bbs2-0041" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. National Journal of Cancer Institute1993;85(5):365‐76. ">Aaronson 1993</a>) and BR23 (<a href="./references#CD003860-bbs2-0093" title="SprangersMA , GroenvoldM , ArrarasJI , FranklinJ , teVeldeA , MullerM , et al. The European Organization for Research and Treatment of Cancer breast cancer‐specific quality‐of‐life questionnaire module: first results from a three‐country field study. Journal of Clinical Oncology1996;14(10):2756‐68. ">Sprangers 1996</a>) were used, with a questionnaire at baseline, 6, 12, 24 and 60 months after RT. <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> evaluated quality of life at six months, using FACT‐B (<a href="./references#CD003860-bbs2-0049" title="BradyMJ , CeliaDF , MoF , BonomiAE , TulskyDS , LloydSR , et al. Reliability and validity of the Functional Assessment of Cancer Therapy‐Related Breast quality‐of‐life instrument. Journal of Clinical Oncology1997;15(3):974‐86. ">Brady 1997</a>; <a href="./references#CD003860-bbs2-0099" title="WebsterK , CelieD , YostK . The Functional Assessement of Chronic Illness Therapy (FACIT) Measurement System: properties, applications and interpretation. Health Quality of Life Outcomes2003;1:79. ">Webster 2003</a>), FACT‐G (<a href="./references#CD003860-bbs2-0060" title="FaircloughDL , CelieDF . Functional assessment of cancer therapy. Quality of Life Research1996;5(3):321‐9. ">Fairclough 1996</a>), BIS (<a href="./references#CD003860-bbs2-0071" title="HopwoodP , FletcherI , LeeA , Al GhazalS . A body image scale for use with cancer patients. European Journal of Cancer2001;37:189‐97. ">Hopwood 2001</a>), Appearance Schemas Inventory‐Revised (ASI‐R), and included both participant‐ and physician‐reported fatigue. </p> </section> <section id="CD003860-sec-0083"> <h6 class="title">Costs</h6> <p>Costs were not reported.</p> </section> </section> <section id="CD003860-sec-0084"> <h5 class="title">Follow‐up</h5> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> had a median follow‐up of 37.3 months. <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> had a median follow‐up of 9.7 years. <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> had a median follow‐up of seven months. <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> reported at a median follow‐up of 42 months. <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> had a median follow‐up of 9.3 years. <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> had a median follow‐up of 9.9 years. <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> reported cosmesis at a median follow‐up of 22 months. <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> had a median follow‐up of 12 years. <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> had "minimum follow up of six months." </p> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> addressed non‐inferiority: <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> was an equivalence study. There was inadequate detail to assess <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> in this respect. </p> <p>Further detail is available in the <a href="./references#CD003860-sec-0174" title="">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD003860-sec-0085"> <h4 class="title">Excluded studies</h4> <p>Fifty‐three studies were reviewed in full, of these, 25 were excluded (see <a href="./references#CD003860-sec-0175" title="">Characteristics of excluded studies</a>). </p> <section id="CD003860-sec-0086"> <h5 class="title">Studies awaiting classification</h5> <p>No studies await classification.</p> </section> <section id="CD003860-sec-0087"> <h5 class="title">Ongoing studies</h5> <p>We identified five ongoing studies (see <a href="./references#CD003860-sec-0176" title="">Characteristics of ongoing studies</a>). </p> </section> </section> </section> <section id="CD003860-sec-0088"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD003860-sec-0089"> <h4 class="title">Summary assessment of risk of bias</h4> <p>For the outcome LR‐FS, one study (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) was deemed at high risk of bias, but this was for subjective outcomes, so was unlikely to have made this outcome at high risk of bias. </p> <p>Cosmesis: one study (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) was deemed at high risk of bias, so we felt that for the domain of subjective outcomes this outcome was at high risk of bias. </p> <p>Overall survival: although two studies were deemed at high risk of bias for some subjective outcomes, for this objective outcome, we did not deem this outcome to be at high risk of bias. </p> <p>Toxicity: no study reporting acute toxicity was deemed at high risk of bias. <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> was deemed at high risk of bias for no blinding for subjective outcomes. We felt this would have had an impact on the subjective outcome of late RT toxicity. </p> <p>Cancer‐specific survival: although <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> was at high risk of bias, we did not feel it would impact on this outcome. </p> <p>Relapse‐free survival: although <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> was at high risk of bias, we did not feel it would impact on this outcome. </p> <p>Mastectomy rate: because this is an objective outcome, we did not feel it was a high risk of bias. </p> <p>Quality of life: the most reliable information would come from patient‐reported outcomes, so assessment of risk of bias for this outcome would require information about how the data were collected. </p> <p>Costs: we did not feel this was at high risk of bias. RIsk of bias is summarised in <a href="#CD003860-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD003860-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD003860-sec-0090"> <h4 class="title">Allocation</h4> <p>Sequence generation was adequate for the following studies: <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>; for <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> this was unclear. We know for <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>, <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> that this allocation was computer‐generated. In <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> there was inadequate detail with respect to the method used for sequence generation. </p> <p>Concealment of allocation was adequate for <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. Computer‐generated permuted blocks were used in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, which may allow prediction of the next randomisation in the sequence. If those undertaking recruitment are not aware that permuted blocks are being used, or the block size, then this should not distort the recruitment. In <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> the process was central, although not explicitly described as concealed. In <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> "closed envelopes" were used, but few details given about the process used. In <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> there were no details given about allocation concealment and inadequate details ("were randomly assigned") in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>. </p> </section> <section id="CD003860-sec-0091"> <h4 class="title">Blinding</h4> <section id="CD003860-sec-0092"> <h5 class="title">Subjective outcomes</h5> <p>In <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, the participants and personnel were not mentioned as blinded (which was unlikely to have an impact on risk of bias), but we judged <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> to be at high risk of bias because the likely lack of blinding (not mentioned) could have introduced bias, particularly for assessment of cosmesis. </p> <p>No details about blinding participants, personnel or assessors were given in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> for subjective outcomes so these were deemed at unclear risk of bias. </p> <p>In <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> the participants and personnel were not mentioned as blinded (unlikely to have impact on risk of bias) and although the assessors of acute toxicity were not blinded, the use of a pre‐specified toxicity scale reduced the associated risk of bias and as quality of life used participant‐reported outcomes, this domain was judged to be at low risk of bias. </p> <p>In <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> the participants and personnel were not mentioned as blinded (unlikely to have an impact on risk of bias). The assessors for photographic appearance (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) were blinded which was most important for assessment of this subjective primary outcome, so we judged this at low risk of bias. </p> <p>The assessors for photographic appearance (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>) were blinded which was most important for assessment of this subjective primary outcome, so we judged this at low risk of bias. Clinical assessments were not blinded (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>), although they were done by many people, which may potentially reduce the risk of bias, so we judged this outcome to be at low risk of bias. </p> <p>Although assessment of acute RT toxicity was not described as blinded, the assessment of cosmetic outcome was blinded in <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> so we judged it to be at low risk of bias. </p> </section> <section id="CD003860-sec-0093"> <h5 class="title">Objective outcomes</h5> <p>Blinding was not mentioned in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> or <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> therefore it was probably not done. The time points for clinical examinations were pre‐specified, but the timing for mammography was not reported in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> or <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. There may have been lead time bias in diagnosis of local recurrence by un‐blinded assessors, so we deemed this outcome to be at unclear risk of bias for these studies. Blinding of outcome assessors was not mentioned in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, therefore probably not done, however, lead time bias in diagnosis of local recurrence by un‐blinded clinical assessors would be reduced by the pre‐specified mammography and clinical examination intervals in <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, so we judged this outcome to be at low risk of bias. In <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>, the study was described as "open", which suggests it was not blinded, so judged to be at low risk of bias. Blinding of assessors for objective outcomes: no details were given in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> (deemed at unclear risk of bias). No objective outcomes were reported in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> (as they were interim reports) and we deemed them to be at unclear risk of bias. <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> was not blinded, but deemed to be at low risk of bias. </p> </section> </section> <section id="CD003860-sec-0094"> <h4 class="title">Incomplete outcome data</h4> <section id="CD003860-sec-0095"> <h5 class="title">Subjective outcomes</h5> <p>In <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>, 1202/1410 women had photos at both baseline and at a later time point for the subjective cosmetic and toxicity outcomes assessment. Reasons for attrition were not detailed, but the number of women without a photo comprised less than 15% of the cohort, so we judged it at low risk of bias. No details were given with respect to attrition in <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>. In <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>, 1306/2236 enrolled in the photographic study: assessed in 1055 participants with both a baseline and a follow‐up photograph. In <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> 1094/2215 enrolled in the photographic study. For both <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> it is not clear why not all participants were enrolled, a source of possible bias, so deemed at unclear risk of bias. </p> <p>Cosmetic outcome was assessed in 735/1220 women; those who had follow‐up to five years at the time of the initial trial report (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). It may be that the reason others did not have five years follow‐up is because they had not been in the trial long enough, but it could also potentially be due to other reasons, perhaps because of withdrawal or non‐attendance, a possible source of bias. </p> <p>Late radiation toxicity was assessed in 752/1220 women at five years. It may be that not all women had five years follow‐up, but this is not made clear (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). The authors make the point that most of the toxic effects of radiotherapy are evident by five years follow‐up. </p> <p>For quality of life, the first 806/1410 women were selected to enrol in the prospectively collected physician assessments (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>). In <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, 1079/2215 enrolled in the quality‐of‐life study. It is not clear how the participants enrolled in the quality‐of‐life study were selected in both studies (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) so we deemed it to be at unclear risk of bias. No details regarding attrition were given in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>, so this was deemed at unclear risk of bias. For <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>, attrition was clearly reported by study arm, so was deemed to be at low risk of bias. </p> </section> <section id="CD003860-sec-0096"> <h5 class="title">Objective outcomes</h5> <p>For <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> and <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> there were explicit details given with respect to the numbers lost to follow‐up and the reasons (per treatment arm) given. Attrition was clearly described in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>. In <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> there was no detail given regarding attrition, which is a potential source of bias. No details regarding attrition were given in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> or <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>. There were no objective outcomes reported in the first study reports of <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>, but they are likely to be reported in the future, so we deemed them to be at unclear risk of bias. </p> </section> </section> <section id="CD003860-sec-0097"> <h4 class="title">Selective reporting</h4> <p>All nine studies reported most of the outcomes detailed in the methods, but we were not able to review the protocols. <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> have not yet reported the health economics consequences. Without comparing the reports with the trial protocols, we could not be sure all outcomes had been reported. Therefore we judged them all at unclear risk of bias. </p> </section> <section id="CD003860-sec-0098"> <h4 class="title">Other potential sources of bias</h4> <p>Some studies were potentially biased by early reporting. <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> reported "minimum 5 year follow‐up" for the subjective primary outcome, so we judged it to be at unclear risk of bias. The trial was stopped early because the <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> trials started. For the subjective outcome assessed photographically in both <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, not all women were assessed at five years, so it is possible that only a small number of women were assessed with five years' follow‐up. We found no other sources of bias in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> (so we judged this domain at low risk of bias). There was inadequate detail given to judge <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> and <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> (deemed at unclear risk of bias). For <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, we did not identify any other potential sources of bias. </p> </section> </section> <section id="CD003860-sec-0099"> <h3 class="title" id="CD003860-sec-0099">Effects of interventions</h3> <p>See: <a href="./full#CD003860-tbl-0001"><b>Summary of findings for the main comparison</b> Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</a> </p> <p>In the results presented, ratios of treatment effects are given such that HRs and RRs greater than 1.0 would indicate a beneficial effect of altered fraction size over conventional fractionation (although, as noted below, most of these results were not statistically significant). </p> <section id="CD003860-sec-0100"> <h4 class="title">Primary outcomes</h4> <section id="CD003860-sec-0101"> <h5 class="title">Local recurrence‐free survival</h5> <p>We studied 442 local recurrences in 8050 women enrolled in six studies.</p> <p>For the comparison of altered fraction size versus conventional fractionation we found that there was no clinically meaningful difference in local recurrence‐free survival: HR 0.18 (95% CI 0.03 to 1.13) using observed events at 3.5 years and a HR 0.94 (95% CI 0.77 to 1.15) using observed events at ten years (<a href="./references#CD003860-fig-0007" title="">Analysis 1.1</a>; <a href="#CD003860-fig-0003">Figure 3</a>). In absolute terms, this means 4 fewer local recurrences per 1000 women at median follow‐up ten years (95% CI 14 fewer to 9 more). This represents 1.4% fewer local relapses (95% CI 1.6% fewer to 1.0% more) i.e. clinically meaningful harms or benefits have been excluded. Specifically, altered fractionation is non‐inferior, not more than 2.5% worse than conventional fractionation. We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.54 (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). </p> <div class="figure" id="CD003860-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.1 Local recurrence‐free survival (LR‐FS)." data-id="CD003860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.1 Local recurrence‐free survival (LR‐FS). </p> </div> </div> </div> <section id="CD003860-sec-0102"> <h6 class="title">Sensitivity analysis</h6> <p>Our results were robust to sensitivity analysis, we excluded studies deemed at high risk of bias (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). We found no difference in LR‐FS: HR 0.94, 95% CI 0.76 to 1.17, P = 0.57. We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.45. </p> </section> <section id="CD003860-sec-0103"> <h6 class="title">Subgroup analysis</h6> <p>We did subgroup analysis by:</p> <p> <ol id="CD003860-list-0009"> <li> <p>dose in the experimental arm &lt; 50 Gy (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) and ≥ 50 Gy (<a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>): HR 0.89 (95% CI 0.70 to 1.14, P = 0.36; <a href="./references#CD003860-fig-0008" title="">Analysis 1.2</a>). We found no heterogeneity: I<sup>2</sup> = 0%, P = 0.53. We tested for statistical difference between the subgroups (Chi<sup>2</sup> = 0.27, I<sup>2</sup> = 0%, P = 0.60) and found no difference between the subgroups; </p> </li> <li> <p>length of follow‐up 4.2 years versus 9.3 to 12 years. We tested for statistical difference between the subgroups (I<sup>2</sup> = 0%, P = 0.58) and found no difference between the subgroups. </p> </li> </ol> </p> </section> </section> <section id="CD003860-sec-0104"> <h5 class="title">Cosmesis: appearance (objective and subjective) of the post‐treatment breast</h5> <p>We found no clinically meaningful difference in cosmesis for the comparison of altered fraction size versus conventional fractionation (687 events, 2103 women, four studies): RR 0.90, 95% CI 0.81 to 1.01, P = 0.08 (<a href="./references#CD003860-fig-0009" title="">Analysis 1.3</a>; <a href="#CD003860-fig-0004">Figure 4</a>). In absolute terms, this represents 31 fewer women with poor or fair cosmetic outcome per 1000 women treated with altered fraction size (95% CI 59 fewer to 3 more), i.e. clinically meaningful harms have been excluded, but there may be meaningful benefit. We found little evidence of heterogeneity, I<sup>2</sup> = 15%, P = 0.32 (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) (<a href="./references#CD003860-fig-0009" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD003860-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.3 Cosmesis (fair/poor)." data-id="CD003860-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.3 Cosmesis (fair/poor). </p> </div> </div> </div> <section id="CD003860-sec-0105"> <h6 class="title">Sensitivity analysis</h6> <p>We excluded studies deemed at high risk of bias (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). We found that there may be an improvement in cosmesis for the comparison of altered fraction size versus conventional fractionation: RR 0.89, 95% CI 0.79 to 1.00, P = 0.06. There may be some heterogeneity; I<sup>2</sup> = 40%, P = 0.19. </p> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> reported photographic assessment of change in breast appearance for those women treated with breast conserving surgery (median follow‐up of 6.0 years, maximum 6.2 years) using a three‐point scale. A total of 1055 women (see <a href="#CD003860-sec-0063">Description of studies</a>) were assessed at a mix of two and five years and were dichotomised into mild or marked change or no change (figures reported from text). For comparison of 41.6 Gy versus 50 Gy: HR 1.09 (95% CI 0.85 to 1.40, P = 0.62). For comparison of 39 Gy versus 50 Gy: HR 0.69 (95% CI 0.52 to 0.91, P = 0.01). </p> <p><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> reported photographic assessment of change in breast appearance for those women treated with breast conserving surgery (median follow‐up of 5.1 years, maximum six years) using a three‐point scale. A total of 923 women (see <a href="#CD003860-sec-0063">Description of studies</a>) were assessed at a mix of two and five years and were dichotomised into mild or marked change or no change (figures reported from text): HR 0.83 (95% CI 0.66 to 1.04, P = 0.06). </p> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> reported minimum five‐year follow‐up for any or marked change in breast appearance and found no significant difference between the altered and conventional arms for any change: RR 1.01 (95% CI 0.88 to 1.17, P = 0.86) or for marked change: RR 1.24 (95% CI 0.77 to 2.00, P = 0.37). There was no difference in moderate or marked breast distortion between the two trial arms: RR 1.01 (95% CI 0.87 to 1.17, P = 0.90). </p> </section> </section> </section> <section id="CD003860-sec-0106"> <h4 class="title">Secondary outcomes</h4> <section id="CD003860-sec-0107"> <h5 class="title">Overall survival</h5> <p>We studied 991 deaths in 5685 women enrolled in three studies. For the comparison of altered fraction size versus conventional fractionation we found that there was no clinically meaningful effect on survival (median survival 9.3 to 9.9 years): HR 0.91 (95% CI 0.80 to 1.03, P = 0.15; <a href="./references#CD003860-fig-0010" title="">Analysis 1.4</a>; <a href="#CD003860-fig-0005">Figure 5</a>). In absolute terms, there were 13 fewer deaths per 1000 women treated with altered fraction size (95% CI 31 fewer to 5 more). This represents 1.3% fewer deaths (95% CI 3.1% fewer to 0.5% more) i.e. clinically meaningful harms or benefits have been excluded. Specifically, altered fractionation is non‐inferior, not more than 2.5% worse than conventional fractionation. We found little evidence of heterogeneity, I<sup>2</sup> = 19%, P = 0.29 (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). </p> <div class="figure" id="CD003860-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.4 Overall survival (OS)." data-id="CD003860-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.4 Overall survival (OS). </p> </div> </div> </div> <section id="CD003860-sec-0108"> <h6 class="title">Sensitivity analysis</h6> <p>Our results were robust to the exclusion of the study at high risk of bias (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) with a HR 0.90 (95% CI 0.78 to 1.04). We found evidence of heterogeneity (I<sup>2</sup> = 58%, P = 0.12). </p> </section> </section> <section id="CD003860-sec-0109"> <h5 class="title">Toxicity</h5> <p>This outcome covers acute and late effects of radiation therapy, and chemotherapy‐related toxicity. </p> <p>Individual protocol‐based definitions were used. Toxicity and late effects were reported on assessable numbers. </p> <section id="CD003860-sec-0110"> <h6 class="title">Acute radiation skin toxicity</h6> <p>We studied acute radiation skin toxicity: 93 events were reported in 357 women enrolled in two studies (<a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a>). Acute radiation toxicity was decreased by a clinically meaningful amount in the altered fractionation arm: RR 0.32, 95% CI 0.22 to 0.45, P &lt; 0.00001. There may be some heterogeneity: (I<sup>2</sup> = 78%, P = 0.03; <a href="./references#CD003860-fig-0011" title="">Analysis 1.5</a>). </p> <p>In <a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> more acute skin toxicity was reported in the altered fractionation arm at seven to 10 days (90% versus 66.3%, P = 0.204; figures from text). </p> <p>"Two patients (both 50 Gy in 25 fractions) experienced an unusually marked acute skin reaction during their radiation therapy, culminating in extensive moist desquamation" in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>. </p> <p>In <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, "an unusually marked acute reaction during radiotherapy was recorded for 16 patients (13 after 50 Gy), three after 40 Gy. Of these, 14 cases were severe skin reactions (extensive moist desquamation)" (not reported by study arm). </p> </section> <section id="CD003860-sec-0111"> <h6 class="title">Late radiation toxicity</h6> <section id="CD003860-sec-0112"> <p><b>Late skin toxicity</b></p> <p>Skin toxicity was reported at 12 years: there were 39 events in 455 women from one study (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). No woman had severe (Grade IV) skin toxicity. There was no clinically meaningful increase in late RT skin toxicity for women treated with altered fraction size RR 1.09 (95% CI 0.60 to 1.99, P = 0.77). In absolute terms, three more per 1000 women treated with altered fraction size (95% CI 15 fewer to 36 more), i.e. clinically meaningful harms or benefits have not been excluded. A test for heterogeneity was not applicable with only one trial. </p> </section> <section id="CD003860-sec-0113"> <p><b>Late radiation subcutaneous toxicity</b></p> <p>This did not differ at:</p> <p> <ol id="CD003860-list-0010"> <li> <p>five years: RR 1.07 (95% CI 0.85 to 1.35, P = 0.55, 806 participants, 1 study (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>) (<a href="./references#CD003860-fig-0013" title="">Analysis 1.7</a>); </p> </li> <li> <p>10 years: RR 0.89 (95% CI 0.78 to 1.02, P = 0.10, 4324 participants, 2 studies (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) (<a href="./references#CD003860-fig-0013" title="">Analysis 1.7</a>). </p> </li> </ol> </p> <p>We found no clinically meaningful difference in late radiation subcutaneous toxicity (975 events in 5130 women, four studies) for women treated with altered fraction size: RR 0.93, 95% CI 0.83 to 1.05, P = 0.24). In absolute terms, we found no fewer women with late RT toxicity per 1000 women treated with altered fraction size (95% CI 1 fewer to 0 more), i.e. clinically meaningful harms or benefits have been excluded. We found no heterogeneity: I<sup>2</sup> = 0%, P = 0.40. Test for subgroup difference, Chi<sup>2</sup> = 1.81, I<sup>2</sup> = 44.7%. </p> </section> <section id="CD003860-sec-0114"> <p><b>Late induration (sub‐cutaneous fibrosis)</b></p> <p>Measured at six months post RT this was "comparable" between the two arms (<a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; no figures given). </p> </section> <section id="CD003860-sec-0115"> <p><b>Telangiectasia</b></p> <p>Telangiectasia (190 events in 4632 women, three studies) was reduced by a clinically meaningful amount in women treated with altered fraction size compared with conventional fractionation: RR 0.68 (95% CI 0.52 to 0.91, P = 0.009; <a href="./references#CD003860-fig-0014" title="">Analysis 1.8</a>). In absolute terms, we found 16 fewer women developed telangiectasia with altered fraction size (95% CI 4 fewer to 23 fewer). We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.85. Telangiectasia, measured at six months post RT was "comparable" between the two arms (<a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; no figures given). </p> </section> <section id="CD003860-sec-0116"> <p><b>Breast oedema</b></p> <p>Breast oedema (332 events in 4140 women, three studies) was reduced by a clinically meaningful amount in women treated with altered fraction size compared with conventional fractionation: RR 0.63 (95% CI 0.51 to 0.78, P &lt; 0.0001; <a href="./references#CD003860-fig-0015" title="">Analysis 1.9</a>). In absolute terms, 36 fewer women developed breast oedema with altered fraction size (95% CI 21 fewer to 48 fewer) i.e. clinically meaningful benefit has not been excluded. We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.43. Breast oedema, measured at six months post RT was "comparable" between the two arms (<a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a>; no figures given). </p> </section> <section id="CD003860-sec-0117"> <p><b>Breast shrinkage</b></p> <p>Breast shrinkage (950 events in 3869 women, two studies) did not differ by a clinically meaningful amount for the comparison of altered fraction size versus conventional fractionation: RR 0.89 (95% CI 0.79 to 1.00, P = 0.04; <a href="./references#CD003860-fig-0016" title="">Analysis 1.10</a>). In absolute terms, 26 fewer women developed breast shrinkage with the use of altered fraction size (95% CI 0 fewer to 49 fewer), i.e. clinically meaningful harms or benefits have been excluded. We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.54. </p> </section> <section id="CD003860-sec-0118"> <p><b>Ischaemic heart disease</b></p> <p>Ischaemic heart disease in women with left‐sided tumours (18 events in 4451 women, two studies: <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>) appeared reduced by a clinically meaningful amount for the comparison of altered fraction size versus conventional fractionation: RR 0.71 (95% CI 0.28 to 1.79, P = 0.47). In absolute terms, one fewer woman developed ischaemic heart disease with altered fraction size (95% CI 3 fewer to 4 more), i.e. clinically meaningful harms or benefits have not been excluded. There was no heterogeneity: I<sup>2</sup> = 0%, P = 0.80 (<a href="./references#CD003860-fig-0017" title="">Analysis 1.11</a>). </p> </section> <section id="CD003860-sec-0119"> <p><b>Rib fractures</b></p> <p>Incidence of rib fractures (8 events in 5685 women, three studies: <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) was reduced by a clinically insignificant amount for the comparison of altered fraction size versus conventional fractionation: RR 0.87 (95% CI 0.25 to 3.10, P = 0.83). In absolute terms, no fewer women developed rib fractures with altered fraction size (95% CI 1 fewer to 3 more) i.e. clinically meaningful harms or benefits have not been excluded. There was no heterogeneity (I<sup>2</sup> = 0%, P = 0.78; <a href="./references#CD003860-fig-0018" title="">Analysis 1.12</a>). </p> </section> </section> </section> <section id="CD003860-sec-0120"> <h5 class="title">Breast cancer‐specific survival</h5> <p>We studied 673 breast cancer deaths in 5685 women enrolled in three studies (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>). For the comparison of altered fraction size versus conventional fractionation we found that there was no clinically meaningful difference for the outcome of breast cancer‐specific survival: HR 0.91 (95% CI 0.78 to 1.06, P = 0.21; <a href="./references#CD003860-fig-0019" title="">Analysis 1.13</a>; <a href="#CD003860-fig-0006">Figure 6</a>). In absolute terms, we found 10 fewer breast cancer deaths per 1000 women treated with altered fraction size (95% CI 25 fewer to 7 more). This represents 1.0% fewer breast cancer deaths (95% CI 2.5% fewer to 0.7% more) with altered fractionation i.e. clinically meaningful harms or benefits have been excluded. Specifically, altered fractionation is non‐inferior, not more than 2.5% worse than conventional fractionation. We found no evidence of heterogeneity: I<sup>2</sup> = 0%, P = 0.42 (<a href="./references#CD003860-fig-0019" title="">Analysis 1.13</a>). </p> <div class="figure" id="CD003860-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.13 Breast cancer‐specific survival." data-id="CD003860-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.13 Breast cancer‐specific survival. </p> </div> </div> </div> </section> <section id="CD003860-sec-0121"> <h5 class="title">Relapse‐free survival</h5> <p>We studied 870 relapses in 5685 women enrolled in three studies. We found no clinically meaningful evidence that the use of hypofractionation was detrimental to relapse‐free survival (<a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>): HR 0.93, 95% CI 0.82 to 1.05, P = 0.24 (<a href="./references#CD003860-fig-0020" title="">Analysis 1.14</a>). In absolute terms, we found 14 fewer relapses per 1000 women treated with altered fraction size (95% CI 36 fewer to 10 more). This represents 1.4% fewer relapses (95% CI 3.6% fewer to 1.0% more) i.e. clinically meaningful harms or benefits have been excluded. Specifically, altered fractionation is non‐inferior, not more than 2.5% worse than conventional fractionation. i.e. clinically meaningful benefits or harms have been excluded. We found some evidence of heterogeneity, I<sup>2</sup> = 62% , P = 0.07. </p> <section id="CD003860-sec-0122"> <h6 class="title">Sensitivity analysis</h6> <p>These results were robust to sensitivity analysis. We excluded a study deemed at high risk of bias (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>): HR 0.90, 95% CI 0.78 to 1.03. We found evidence of heterogeneity: I<sup>2</sup> = 74%, P = 0.05. </p> </section> </section> <section id="CD003860-sec-0123"> <h5 class="title">Mastectomy rate</h5> <p>No data.</p> </section> <section id="CD003860-sec-0124"> <h5 class="title">Quality of life (trial‐specific instruments)</h5> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> reported less patient‐reported fatigue (P &lt; 0.001) and physician‐reported fatigue (P = 0.009) for those women treated with altered fraction size (figures from text) compared to women treated with conventional fractionation at six months. <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> reported no difference in mean FACT‐B scores from baseline to six months for the following outcomes: physical well‐being (P = 0.46), functional well‐being (P = 0.38), emotional well‐being (P = 0.58), social well‐being (P = 0.32), FACT‐G total score (P = 0.73), breast cancer concerns (P = 0.94) and FACT‐B total score (P = 0.79). </p> </section> <section id="CD003860-sec-0125"> <h5 class="title">Costs (to women and health services)</h5> <p>No data.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003860-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003860-sec-0126"></div> <section id="CD003860-sec-0127"> <h3 class="title" id="CD003860-sec-0127">Summary of main results</h3> <p>We deemed that the Hazard Ratio of 0.75 or less and 1.25 or more was clinically meaningful and if the 95% confidence interval was greater than 0.75 or less and 1.25 or more, clinically meaningful benefits or harms had not been excluded. For the outcomes of local recurrence‐free survival, overall survival, breast cancer‐specific survival and relapse‐free survival, we determined (post‐hoc) the MID was 2.5%. </p> <section id="CD003860-sec-0128"> <h4 class="title">Local recurrence‐free survival</h4> <p>For these comparisons, there appears to be no clinically meaningful difference between the fractionation techniques for local recurrence‐free survival, and clinically meaningful benefits or harms have been excluded. </p> </section> <section id="CD003860-sec-0129"> <h4 class="title">Breast appearance (cosmesis)</h4> <p>For this comparison, there appears to be no clinically meaningful difference between the fractionation techniques for cosmetic outcome, and clinically meaningful benefits or harms have been excluded. </p> </section> <section id="CD003860-sec-0130"> <h4 class="title">Overall survival</h4> <p>For this comparison, there was no clinically meaningful difference between the fractionation techniques, and clinically meaningful benefits or harms have been excluded. </p> </section> <section id="CD003860-sec-0131"> <h4 class="title">Acute RT skin toxicity</h4> <p>For these comparisons, there appears to be a clinically meaningful reduction in acute RT toxicity when altered fraction size is used versus conventional fractionation. </p> </section> <section id="CD003860-sec-0132"> <h4 class="title">Late RT toxicity</h4> <p>For the comparison of altered fraction size versus conventional fractionation for the following outcomes there was no difference: late skin toxicity, late subcutaneous toxicity, breast shrinkage, ischaemic heart disease and rib fractures. Both telangiectasia and breast oedema were reduced in women who had altered fraction size, compared with conventional fractionation. </p> </section> <section id="CD003860-sec-0133"> <h4 class="title">Breast cancer‐specific survival</h4> <p>For this comparison, we found no clinically meaningful difference between the fractionation techniques, and clinically meaningful benefits or harms have been excluded. </p> </section> <section id="CD003860-sec-0134"> <h4 class="title">Relapse‐free survival</h4> <p>For this comparison, we found no clinically meaningful difference between the fractionation techniques, and clinically meaningful benefits or harms have been excluded. </p> </section> <section id="CD003860-sec-0135"> <h4 class="title">Mastectomy rate</h4> <p>For this comparison, we found no data with respect to subsequent mastectomy rates.</p> </section> <section id="CD003860-sec-0136"> <h4 class="title">Quality of life</h4> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> reported less patient‐ and physician‐reported fatigue for those women treated with altered fraction size. <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> reported no difference in mean FACT‐B scores for: physical well‐being (P = 0.46), functional well‐being (P = 0.38), emotional well‐being (P= 0.58), social well‐being (P = 0.32), FACT‐G total score (P = 0.73), breast cancer concerns (P = 0.94) and FACT‐B total score (P = 0.79). </p> </section> <section id="CD003860-sec-0137"> <h4 class="title">Costs</h4> <p>We found no data with respect to costs or women's preference for either altered or conventional fractionation. </p> <p>For women with early breast cancer, achieving and maintaining local control in addition to maximising survival are the main goals of management. Whilst conservative surgery followed by radiation therapy allows preservation of the breast, the requirement for five to six weeks of radiation therapy, which may only be available at some distance from the woman's residence, can be a burden. The many costs involved (monetary and other) may mean that women choose mastectomy over breast‐conserving therapy to avoid the necessity for radiation therapy (<a href="./references#CD003860-bbs2-0077" title="NattingerAB , KneusalRT , HoffmanRG , GilliganMA . Relationship of distance from a radiotherapy facility and initial breast cancer treatment. Journal of the National Cancer Institute2001;93(17):1344‐6. ">Nattinger 2001</a>). </p> <p>Shortening the duration of postoperative breast radiation would provide the advantage of shorter disruption of normal activities and less time away from home and family. Reducing the number of fractions required would also free up radiation therapy machine time. This may reduce waiting lists and improve timely access to radiation therapy for other people with cancer. The ability to reduce the number of fractions required to treat women with early breast cancer safely may, therefore, result in many benefits at a personal, national and international level provided acceptable local control, toxicity and survival can be maintained with this approach. </p> <p>This review set out to explore whether shortened (altered fraction size) regimens used to treat women who have had conservative surgery for early breast cancer can offer the same tumour control and cosmetic results as longer fractionation regimens. We have been able to include data from nine randomised controlled trials that compared different fractionation schemes. The comparison studied is altered fraction size (fraction size greater than 2 Gy) versus conventional fractionation (2 Gy per fraction). </p> <p>The findings of this review provide reassurance that the practice of offering shortened radiation fractionation regimens to carefully selected groups of women with early breast cancer is equivalent in terms of local control, breast appearance, survival and late radiation breast toxicity, with associated improvements in some cosmetic parameters (telangiectasia and breast oedema). </p> </section> </section> <section id="CD003860-sec-0138"> <h3 class="title" id="CD003860-sec-0138">Overall completeness and applicability of evidence</h3> <section id="CD003860-sec-0139"> <h4 class="title">Participants</h4> <p>These results are mostly applicable to women with small to medium breasts, aged greater than 50 years, with node negative tumours less than 3 cm in size, with negative pathological margins. </p> <p>Sixty‐eight percent (5332/7824) of the women enrolled in the nine studies were node negative (see <a href="#CD003860-tbl-0005">Table 4</a>) and 100% of the women studied in this review had negative pathological margins (not stated in <a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> or <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>). T3 tumours (larger than 5 cm) account for 9% (724/7513) of the total number of women studied. Most women studied in this review had small to medium breasts (83%; 4859/5845, where breast size was reported). </p> </section> <section id="CD003860-sec-0140"> <h4 class="title">Treatment and follow‐up</h4> <p>The length of follow‐up was not adequate to detect differences in breast cancer mortality (not apparent before 15 years' follow‐up) (<a href="./references#CD003860-bbs2-0058" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG), DarbyS , McGaleP , CorreaC , TaylorC , ArriagadaR , ClarkeM , et al. Effect of radiotherapy after breast‐conserving surgery on 10‐year recurrence and 15‐year breast cancer death: meta‐analysis of individual patient data for 10,801 women in 17 randomised trials.. Lancet2011;378:1707‐16. ">EBCTCG 2011</a>). If, however, there are truly no differences in local recurrence or late toxicity (e.g. cardiac morbidity) one would not expect to see differences in mortality. We did not see an increase in either late RT skin toxicity (<a href="./references#CD003860-fig-0012" title="">Analysis 1.6</a>) or late subcutaneous toxicity (<a href="./references#CD003860-fig-0013" title="">Analysis 1.7</a>) at either five or 10 years' follow‐up. We found no differences in breast shrinkage (<a href="./references#CD003860-fig-0016" title="">Analysis 1.10</a>), rib fractures (<a href="./references#CD003860-fig-0018" title="">Analysis 1.12</a>) or ischaemic heart disease (<a href="./references#CD003860-fig-0017" title="">Analysis 1.11</a>) with longer follow‐up. With respect to radiation therapy‐induced ischaemic heart disease (IHD), there is an excess risk of IHD after radiation therapy which is proportional to the mean heart dose (MHD) received. This increased risk is apparent at four years and persists for many years (<a href="./references#CD003860-bbs2-0053" title="DarbySC , EwertzM , McGaleP , BennetAM , Blom‐GoldmanU , BrønnumD , et al. Risk of ischaemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine2103;368(11):987‐98. ">Darby 2013</a>). It is axiomatic that the reduction in MHD dose received may be of clinical benefit, reducing the risk of IHD for women with left‐sided breast cancer treated with radiation therapy. The use of specialised radiotherapy techniques, such as deep inspiration breath hold (DIBH) can dramatically reduce MHD (<a href="./references#CD003860-bbs2-0059" title="Eldredge‐HindyH , LockamyV , CrawfordA , et al. Active breathing coordinator reduces radiation dose to the heart and preserves local control on patients with left breast cancer: results of a prospective trial. Practical Radiation Oncology2015;5:4‐10. ">Eldrege‐Hindy 2015</a>; <a href="./references#CD003860-bbs2-0091" title="SixtelK , AznarM , UngYC . Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. International Journal of Radiation Oncology, Biology, Physics2001;49(1):199‐204. ">Sixtel 2001</a>). </p> <p>It is possible that the reduction in acute radiotherapy toxicity seen when altered fraction size is used (<a href="./references#CD003860-fig-0011" title="">Analysis 1.5</a>), resulted in a reduction in consequential late radiation‐induced effects, such as telangiectasia (<a href="./references#CD003860-fig-0014" title="">Analysis 1.8</a>) and breast oedema (<a href="./references#CD003860-fig-0015" title="">Analysis 1.9</a>). </p> <p><b>Radiation dose</b> </p> <p>In total, 442 local recurrences were reported in 8050 women. Using an alpha/beta ratio of four for breast tumour cells (<a href="./references#CD003860-bbs2-0063" title="FowlerJ . The linear quadratic formula and progress in fractionated radiotherapy. British Journal of Radiology1989;62(740):679‐94. ">Fowler 1989</a>; <a href="./references#CD003860-bbs2-0094" title="SteelGG , DeaconJM , DuschesneGM , HorwichA , KellandLR , PeacockJH . The dose‐rate effect in human tumour cells. Radiotherapy and Oncology1987;9(4):299‐310. ">Steel 1987</a>; <a href="./references#CD003860-bbs2-0102" title="WilliamsMV , DenekampJ , FowlerJF . A review of alpha/beta ratios for experimental tumours: implications for clinical studies of altered fractionation. International Journal of Radiation Oncology, Biology, Physics1985;11(1):87‐96. ">Williams 1985</a>) allows conversion of radiation doses to EQD<sub>2</sub> (<a href="./references#CD003860-bbs2-0074" title="MaciejewskiB , TaylorJM , WithersHR . Alpha/beta value and the importance of size of dose per fraction for late complications of the supraglottic larynx. Radiotherapy and Oncology1986;7(4):323‐6. ">Maciejewski 1986</a>; <a href="./references#CD003860-bbs2-0104" title="WithersHR , ThamesHDJr , PetersLJ . A new isoeffect curve for change in dose per fraction. Radiotherapy and Oncology1983;1(2):187‐91. ">Withers 1983</a>). When the altered fraction size regimen radiation doses are converted to EQD<sub>2</sub> (see <a href="#CD003860-tbl-0005">Table 4</a>), it is clear that some of the altered regimens (39 Gy in 13 fractions, 42.5 Gy in 13 fractions, 41.6 Gy in 13 fractions and 40 Gy in 15 fractions) (<a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a>; <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>; <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) have lower EQD<sub>2</sub> than the conventional 50 Gy in 25 fractions. Subgroup analysis by dose (less than 50 Gy versus 50 Gy) did not reveal any differences: Chi<sup>2</sup> = 0.27, I<sup>2</sup> = 0%, P = 0.06. <a href="./references#CD003860-bbs2-0048" title='PoortmansPM , ColletteL , BartelinkH , StruikmansH , Van denBogaertWF , FourquetA , et al. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881‐10882 "Boost versus no boost" trial. Cancer Radiotherapy2008;12(6):565‐70. '>Bartelink 2008</a> showed that all women irrespective of age showed improved local control with addition of a 16 Gy boost to conventionally fractionated radiotherapy. The reason for the lack of a difference in local control with lower EQD<sub>2</sub> used in the altered fraction size trials is uncertain. Possible reasons include the impact of the boost used in 44% of women treated (see <a href="#CD003860-tbl-0009">Table 8</a>), but it may reflect the effect of the use of more and better systemic therapy which also improves local control. For <a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a>, <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, the use of a boost was roughly equally divided between the treatment arms. While boosts are associated with decreased local recurrence, they are also associated with poorer cosmesis (<a href="./references#CD003860-bbs2-0047" title="BartelinkH , HoriotJC , PoortmansPM , StruikmansH , Van denBogaertW , FourquetA , et al. Impact of a higher radiation dose on local control and survival in breast‐conserving therapy of early breast cancer: 10‐year results of the randomized boost versus no boost EORTC 22881‐10882 trial. Journal of Clinical Oncology2007;25(22):3259‐65. ">Bartelink 2007</a>). </p> <p><b>Cost, peoples' preference and quality of life</b> </p> <p>It has not been possible at this time to answer questions of cost and patient preferences within this review. There was significantly less acute radiation toxicity in the altered arm and one could reasonably expect that shorter regimens are more readily tolerated and, therefore, would enhance the treatment experience for women. The use of altered fraction size was associated with less fatigue (both participant‐ and physician‐reported) and there was no effect on patient‐reported quality‐of‐life measures at six months, suggesting there was no detrimental effect on quality of life. </p> <p>A detailed assessment of quality of life is planned for a subset of women enrolled in <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> and <a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a>, which may provide more information. These data have not yet been reported by study arm, so we could not include them in this version of the review. Little is known about patient preferences in this setting but as rural women have consistently been shown to have more mastectomies in comparison with women who live in bigger centres (<a href="./references#CD003860-bbs2-0077" title="NattingerAB , KneusalRT , HoffmanRG , GilliganMA . Relationship of distance from a radiotherapy facility and initial breast cancer treatment. Journal of the National Cancer Institute2001;93(17):1344‐6. ">Nattinger 2001</a>; <a href="./references#CD003860-bbs2-0090" title="SchroenAT , BreninDA , KellyMD , KnausWA , SlingluffCLJr . Impact of patient distant to radiation therapy on mastectomy use in early‐stage breast cancer patients. Journal of Clinical Oncology2005;23(28):7074‐80. ">Schroen 2005</a>) it may be that they choose mastectomy to reduce their time away from home (assuming they are offered conservative treatment as frequently as women in urban areas). </p> </section> <section id="CD003860-sec-0141"> <h4 class="title">Adjuvant therapies</h4> <p>We do not have information about combining other therapies (for example, trastuzumab) with these fractionation regimens, although observational data suggest it to be a safe practice with conventionally fractionated radiation therapy (<a href="./references#CD003860-bbs2-0089" title="RomondEH , PerezEA , BryantJ , SumanVJ , GeyerCEJr , DavidsonNE , et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. New England Journal of Medicine2005;353(16):1673‐84. ">Romond 2005</a>). </p> </section> <section id="CD003860-sec-0142"> <h4 class="title">Optimum fraction size</h4> <p>The optimum 'dose' of altered fraction size remains unknown. In <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a>; <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a>, two novel altered fraction size schedules were tested, however we were not able to analyse them separately to see if one was superior to the other. We did not find a difference in LR‐FS when we analysed by dose less than 50 Gy versus 50 Gy or more in the experimental arm (test for subgroup difference I<sup>2</sup> = 0%, P = 0.58). In addition, new techniques (such as accelerated partial breast irradiation) shorten treatment time even more by using larger fraction sizes to a smaller volume of breast tissue. These techniques are the subject of a number of ongoing trials. </p> </section> <section id="CD003860-sec-0143"> <h4 class="title">Technological innovations</h4> <p>New technology, for example, intensity modulated radiation therapy (IMRT), which uses multiple radiation beams in order to make treatment highly conformal (thus reducing dose to normal structures) and improve dose distribution has been shown to decrease acute radiotherapy toxicity (<a href="./references#CD003860-bbs2-0056" title="DonovanE , BleakleyN , DenholmE , EvansP , GothardL , HansonJ , et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiotherapy and Oncology2007;82(3):254‐64. ">Donovan 2007</a>) and improve cosmesis (<a href="./references#CD003860-bbs2-0085" title="PignolJP , OlivottoI , RakovitchE , GardnerS , SixelK , BeckhamW , et al. A multicenter randomized trial of breast intensity‐modulated radiation therapy to reduce acute radiation dermatitis. Journal of Clinical Oncology2008;26(13):2085‐92. ">Pignol 2008</a>). </p> </section> </section> <section id="CD003860-sec-0144"> <h3 class="title" id="CD003860-sec-0144">Quality of the evidence</h3> <p>We studied 8228 women enrolled in nine trials. There is now a large body of high quality evidence allowing robust conclusions. </p> <section id="CD003860-sec-0145"> <h4 class="title">Local recurrence‐free survival</h4> <p>For the outcome of LR‐FS we did not downgrade for risk of bias, indirectness, inconsistency (I<sup>2</sup> = 0%, P = 0.61), imprecision (more than 300 events (360), optimum information size (OIS) was met and 95% confidence intervals (CIs) excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'high'. </p> </section> <section id="CD003860-sec-0146"> <h4 class="title">Cosmesis</h4> <p>For the outcome of cosmesis we downgraded for risk of bias, because one study (<a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>) did not blind outcome assessors for subjective outcomes, this study contributed 1220/2103 (60%) of the data for cosmetic outcome. We did not downgrade for indirectness, inconsistency (I<sup>2</sup> = 15% , P = 0.32), imprecision (more than 300 events (687), OIS met and 95% CIs included one, and excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'high'. </p> </section> <section id="CD003860-sec-0147"> <h4 class="title">Toxicity ‐ late subcutaneous fibrosis</h4> <p>For late subcutaneous fibrosis we did not downgrade for risk of bias, as only 5% of events were contributed from a study at high risk of bias for lack of blinding. We did not downgrade for indirectness, or inconsistency (I<sup>2</sup> = 0, P = 0.4). We did not downgrade for imprecision (because there were more than 300 events (975), OIS was met and CIs included one, but excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'high'. </p> <p><b>Overall survival</b> </p> <p>For overall survival we did not downgrade for risk of bias, indirectness or inconsistency (I<sup>2</sup> = 19, P = 0.29). We did not downgrade for imprecision (more than 300 events (991), OIS was met and the CIs included one, and excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'high'. </p> </section> <section id="CD003860-sec-0148"> <h4 class="title">Breast cancer‐specific survival</h4> <p>For breast cancer‐specific survival we did not downgrade for risk of bias (12% of events came from a study deemed at high risk of bias because of a lack of blinding), indirectness, or inconsistency (I<sup>2</sup> = 0%, P = 0.42). We did not downgrade for imprecision (because there were more than 300 events (673), OIS was met and CIs included one, but excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'high'. </p> </section> <section id="CD003860-sec-0149"> <h4 class="title">Relapse‐free survival</h4> <p>For relapse‐free survival, we did not downgrade for risk of bias or indirectness, but did downgrade for inconsistency (I<sup>2</sup> = 74%, P = 0.05). We did not downgrade for imprecision (because there were more than 300 events (673), OIS was met and CIs included one, but excluded clinically meaningful benefits or harms) or publication bias. The GRADE quality of evidence was therefore judged to be 'moderate'. </p> </section> <section id="CD003860-sec-0150"> <h4 class="title">Mastectomy rate</h4> <p>We found no data with respect to this outcome.</p> </section> </section> <section id="CD003860-sec-0151"> <h3 class="title" id="CD003860-sec-0151">Potential biases in the review process</h3> <p>We believe we have identified the relevant studies, and we have identified five ongoing studies (see <a href="./references#CD003860-bbs2-0035" title="AdriaenssensN , DeRidderM , LievensP , VanParijsH , VanhoeijM , MiedemaG , et al. Scapula alata in early breast cancer patients enrolled in a randomized controlled trial of post‐surgery short‐course image‐guided radiotherapy. World Journal of Surgery2012;10:86. AdriaenssensN , Vinh‐HungV , MiedemaG , VersmessenH , LamoteJ , VanhoeijM , et al. Early contralateral shoulder‐arm morbidity in breast cancer patients enrolled in a randomized trial of post‐surgery radiation therapy. Breast Cancer (Auckland)2012;6:79‐93. NCT00459628 . Randomized trial comparing conventional vs short‐course reduced volume conformal post‐surgery radiation treatment in women with stage I or II breast cancer. clinicaltrials.gov/ct2/show/NCT00459628?id=NCT00459628&amp;rank=1 (accessed 30/09/15). VanParijsH , MiedemaG , Vinh‐HungV , VerbanckS , AdriaenssensN , KerkhoveD , et al. Short course radiotherapy with simultaneous integrated boost for stage I‐II breast cancer, early toxicities of a randomized clinical trial. Radiotherapy and Oncology2012;7:80. VersmessenH , Vinh‐HungV , VanParijsH , MiedemaG , VoordeckersM , AdriaenssensN , et al. Health‐related quality of life in survivors of stage I‐II breast cancer: randomized trial of post‐operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer2012;12:495. ">NCT00459628</a>; <a href="./references#CD003860-bbs2-0036" title="NCT00909818 . Hypofractionated versus standard fractionated whole breast irradiation to node‐negative breast cancer patients. clinicaltrials.gov/show/NCT00909818 (accessed 10 June 2010). ">NCT00909818</a>; <a href="./references#CD003860-bbs2-0037" title="NCT01266642 . Randomized trial of hypofractionated whole breast irradiation versus conventionally fractionated whole breast irradiation for ductal carcinoma in situ and early invasive breast cancer. clinicaltrials.gov/ct2/show/NCT01266642 (accessed 13 April 2015). ">NCT01266642</a>; <a href="./references#CD003860-bbs2-0038" title="NCT01349322 . A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early‐stage breast cancer. clinicaltrials.gov/ct2/show/NCT01349322 (accessed 16 April 2015). ">NCT01349322</a>; <a href="./references#CD003860-bbs2-0039" title="NCT01413269 . Phase 3 open‐labeled randomized clinical study of comparing hypofractionated and conventional radiotherapy for breast cancer patients after breast conservative surgery. clinicaltrials.gov/ct2/show/NCT01413269 (accessed 16 April 2015). ">NCT01413269</a>). The ongoing studies will include women treated with more modern chemotherapy agents and hormonal manipulation. </p> <p>There are limitations related to assessment of subjective outcomes, such as cosmesis and breast induration, but this was well‐performed using standardised tools by trained observers in <a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>, with blinding of the outcome assessors to the treatment allocation in <a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011;</a><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008;</a><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008;</a><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a><a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> and <a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a>. </p> </section> <section id="CD003860-sec-0152"> <h3 class="title" id="CD003860-sec-0152">Agreements and disagreements with other studies or reviews</h3> <p>Published guidelines with respect to this question are as follows.</p> <p><a href="./references#CD003860-bbs2-0081" title="NICE . Early and locally advanced breast cancer: Diagnosis and Treatment. nice.org.uk/guidance/cg80/chapter/1‐recommendations#radiotherapy (accessed 14 June 2015). ">NICE</a> guidelines state: "Use external beam radiotherapy giving 40 Gy in 15 fractions as standard practice for patients with early invasive breast cancer after breast conserving surgery or mastectomy". </p> <p><a href="./references#CD003860-bbs2-0079" title="NCCN . NCCN Guidelines Version 2.2015 [Invasive breast cancer]. nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 14 June 2015). ">NCCN</a> guidelines state: "The breast should receive 45‐50 Gy in 23 to 25 fractions or 40 to 42.5 Gy in 15 to 16 fractions (short course is preferred)". </p> <p>American Society for Therapeutic Radiation Oncology (ASTRO) guidelines state: "Evidence from randomized clinical trials has demonstrated that hypo‐fractionated‐ whole breast irradiation (HF‐WBI) and conventionally fractionated (CF)‐WBI are equally effective for in‐breast tumour control and comparable in long term side effects for patients meeting all the criteria listed (see <a href="#CD003860-tbl-0011">Table 10</a>). The task force was unable to reach agreement as to the equivalence of HFWBI to CF‐WBI for patients who do not satisfy all these criteria, and thus, we could not make a recommendation either for or against the use of HF‐WBI in such patients." (<a href="./references#CD003860-bbs2-0092" title="SmithBD , BentzenSM , CorreaCR , HahnCA , HardenbergPH , IbbottGS , et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence‐based guideline. International Journal of Radiation Oncology, Biology, Physics2011;81(1):59‐68. ">Smith 2011</a>). </p> <div class="table" id="CD003860-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ASTRO 'suitable' patients for hypofractionated whole breast radiotherapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient is 50 years or older at diagnosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pathologic stage is T1–2 N0 and patient has been treated with breast conserving surgery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient has not been treated with systemic chemotherapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within the breast along the central axis, the minimum dose is no less than 93% and maximum dose is no greater than 107% of the prescription dose (7%;) (as calculated with 2‐dimensional treatment planning without heterogeneity corrections) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>T: tumour<br/> N: lymph node </p> </div> </div> <p>We found one systematic review of hypofractionation for breast and prostate cancer (<a href="./references#CD003860-bbs2-0086" title="RayKJ , SibsonNR , KiltieAE . Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits. Clinical Oncology2015;27:420‐6. ">Ray 2015</a>). The authors searched Web of Science, PubMed, Google Scholar and ICTRP (search date not reported) as well as trawling reference lists. They conclude: "Hypofractionation in breast cancer treatment is now the standard protocol in the UK. " (<a href="./references#CD003860-bbs2-0086" title="RayKJ , SibsonNR , KiltieAE . Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits. Clinical Oncology2015;27:420‐6. ">Ray 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003860-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for updated review" data-id="CD003860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for updated review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.1 Local recurrence‐free survival (LR‐FS)." data-id="CD003860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.1 Local recurrence‐free survival (LR‐FS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.3 Cosmesis (fair/poor)." data-id="CD003860-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.3 Cosmesis (fair/poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.4 Overall survival (OS)." data-id="CD003860-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.4 Overall survival (OS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.13 Breast cancer‐specific survival." data-id="CD003860-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.13 Breast cancer‐specific survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 1 Local recurrence‐free survival (LR‐FS)." data-id="CD003860-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 1 Local recurrence‐free survival (LR‐FS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 2 LR‐FS by dose." data-id="CD003860-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 2 LR‐FS by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 3 Cosmesis (fair/poor)." data-id="CD003860-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 3 Cosmesis (fair/poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 4 Overall survival (OS)." data-id="CD003860-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 4 Overall survival (OS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 5 Acute skin radiation toxicity." data-id="CD003860-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 5 Acute skin radiation toxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 6 Late skin toxicity." data-id="CD003860-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 6 Late skin toxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 7 Late subcutaneous toxicity (fibrosis))." data-id="CD003860-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 7 Late subcutaneous toxicity (fibrosis)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 8 Telangiectasia." data-id="CD003860-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 8 Telangiectasia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 9 Breast oedema." data-id="CD003860-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 9 Breast oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 10 Breast shrinkage." data-id="CD003860-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 10 Breast shrinkage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 11 Ischaemic heart disease (left‐sided tumours)." data-id="CD003860-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 11 Ischaemic heart disease (left‐sided tumours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 12 Rib fractures." data-id="CD003860-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 12 Rib fractures.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-13.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 13 Breast cancer‐specific survival." data-id="CD003860-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 13 Breast cancer‐specific survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003860-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/urn:x-wiley:14651858:media:CD003860:CD003860-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_t/tCD003860-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofractionation versus conventional fractionation, Outcome 14 Relapse‐free survival." data-id="CD003860-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Hypofractionation versus conventional fractionation, Outcome 14 Relapse‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/media/CDSR/CD003860/image_n/nCD003860-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003860-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women treated with breast conserving therapy for early breast cancer<br/> <b>Setting:</b> cancer centres<br/> <b>Intervention:</b> hypofractionated radiation therapy<br/> <b>Comparison:</b> conventionally fractionated radiation therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventionally fractionated radiation therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with hypofractionated radiation therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Local recurrence‐free survival (LR‐FS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/> (0.77 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7095<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000<br/> (54 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmesis<br/> assessed with fair/poor on 4‐point scale,<br/> follow‐up: range 42 months‐12 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.81 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2103<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1,000<br/> (252 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.80 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000<br/> (135 to 171) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late subcutaneous toxicity<br/> assessed with ≥ Grade 2 on 4‐point scale,<br/> follow‐up: median 6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5130<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1,000<br/> (3 to 4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Breast cancer‐specific survival (BC‐SS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.78 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1,000<br/> (98 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relapse‐free survival (RFS) at 10 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/> (0.82 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5685<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1,000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1,000<br/> (188 to 234) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mastectomy rate ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data with respect to subsequent mastectomy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The baseline risks for the control groups were calculated using 10‐year event data from the included studies<br/> <sup>2</sup> No blinding for assessment of subjective outcomes (for 5% of events only)<br/> <sup>3</sup>Statistical testing as well as examination of the forest plots suggested there was some heterogeneity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">EORTC Cosmetic Rating System</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global cosmetic</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference or excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small difference or good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate difference or fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large difference or poor</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">EORTC Cosmetic Rating System</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RTOG CTCAE acute skin toxicity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No visible change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faint/dull erythema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tender/bright erythema +/‐ dry desquamation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patchy moist desquamation, moderate erythema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confluent moist desquamation, pitting oedema</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RTOG CTCAE acute skin toxicity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTCAE Version 4.0</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild; asymptomatic or mild<br/> symptoms; clinical or diagnostic<br/> observations only; intervention not<br/> indicated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate; minimal, local or<br/> noninvasive intervention indicated;<br/> limiting age‐appropriate<br/> instrumental ADL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe or medically significant but<br/> not immediately life‐threatening;<br/> hospitalisation or prolongation of<br/> hospitalisation indicated; disabling;<br/> limiting self‐care ADL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life‐threatening consequences;<br/> urgent intervention indicated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death related to adverse event</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ADL: activities of daily living</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTCAE Version 4.0</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Conversion of altered fractionation regimen to EQD2 </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fractions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQD<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.9 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control arm dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> <p><a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.5 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> </p> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> <br/> <a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> </p> <p><a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0 Gy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.90</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Conversion of altered fractionation regimen to EQD2 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC late radiation morbidity scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slight toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked toxicity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe toxicity</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC late radiation morbidity scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Induration scale (Owen 2006a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Induration scale (Owen 2006a)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">START A &amp; B Late RT toxicity scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Description</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"none"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"a little"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"quite a bit"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"very much"</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">START A &amp; B Late RT toxicity scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Boost for women treated with breast conservation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>STUDY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast conservation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Boost experimental arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Boost control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0006" title="DewarJA , HavilandJS , AgrawalRK , BlissJM , HopwoodP , MageeB , et al. Hypofractionation for early breast cancer: first results of the UK Standardisation of Breast Radiotherapy (START trials). Journal of Clinical Oncology. 2007; Vol. 25:18 Supplement. HavilandJS , AgrawalR , AirdE , BarrettJ , Barrett‐LeeP , BrownJ , et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10‐year follow‐up results. Cancer Research. 2012; Vol. 72 (24 Supplement):Abstract no: S4‐1. HavilandJS , OwenRJ , DewarJA , AgrawalAK , BarrettJ , Barrett‐LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‐year follow‐up results of two randomised controlled trials. Lancet Oncology2013;14:1086‐94. HopwoodP , HavilandJ , MillsJ , SumoG , BlissJ , on behalf of the START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial). Breast2007;16:241‐51. HopwoodP , HavilandJS , SumoG , MillsJ , BlissJM , Yarnold JR on behalf of the START Trial Management Committee. Comparison of patient‐reported breast, arm and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‐year follow‐up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology2010;11:231‐40. START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. SumoG , HavilandJ , MillsJM , BlissJ , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3, issue 2. ">START A 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6 Gy/13 fractions arm: 391/750 (61%)</p> <p>39 Gy/13 fractions arm: 380/737 (60.5%)</p> <p>Total number with boost: 771/1269 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381/631 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1152/1900 (61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0007" title="SumoG , HavilandJ , MillsJ , BlissJM , YarnoldJ , HopwoodP , reported on behalf of the START Trial Management Group. The effects of radiotherapy on normal tissues in early breast cancer: results of the UK Standardisation of Breast Radiotherapy (START) trials. Clinical Updates in Breast Cancer. 2008; Vol. 3. The START Trialists Group. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet2008;371(9618):1098‐107. ">START B 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446/1018 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422/1020</p> <p>(41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868/2038</p> <p>(43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0002" title="Anon . A RCT comparing 3 radiotherapy fractionation schedules after local surgical excision for early breast cancer. UKCCCR trials register1997. MoodyAM , MaylesWP , BlissJM , A'HernRP , OwenJR , ReganJ , et al. The influence of breast size on late radiation effects and association with radiotherapy dose in homogeneity. Radiotherapy Oncology: Journal of the European Society of Therapeutic Radiology and Oncology1994;33(2):106‐12. OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early‐stage breast cancer after local tumour excision: long term results of a randomised trial. Lancet Oncology2006;7(6):467‐71. YarnoldJ . Phase III randomised study of radiotherapy fractionation regimens after local excision or mastectomy in women with early stage breast cancer. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302000. [Ref ID 4114] YarnoldJ , AshtonA , BlissJ , HomewoodJ , HarperC , HansonJ , et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long‐term results of a randomised trial. Radiotherapy and Oncology2005a;75(1):9‐17. YarnoldJ , OwenR , AshtonA , BroadB , ReganJ , BlissJ , et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: results of a phase III randomised trial. Breast Cancer Research and Treatment2001;69(3):230. YarnoldJR . Randomized study of standard versus hypofractionated adjuvant whole breast radiotherapy in women with localised breast cancer who are at average or low risk of recurrence. cancer.gov/search/viewclinicaltrials.aspx?cdrid=4177302005. [Ref ID: 8041] YarnoldJR , BlissJM , ReganJ , BroadB , DavisonJ , HarringtonF , et al. Randomised comparison of a 13‐fraction schedule with a conventional 25‐fraction schedule of radiotherapy after local excision of early breast cancer: preliminary analysis. Radiotherapy and Oncology 1994a Suppl 1;32:101. YarnoldJR , OwenJR , BlissJ , ReganJ , BroadB , DavidsonJ , et al. Randomized comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer. The Breast1993;2(3):201. YarnoldJR , OwenR , BlissJ . Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. Clinical Oncology1992;4(5):336. YarnoldJR , OwenR , BlissJM , ReganJ , BroadB , DavidsonJ , et al. Randomised comparison of a 13 fraction schedule with a conventional 25 fraction schedule of radiotherapy after local excision of early breast cancer: a preliminary analysis. British Journal of Cancer1994;70(Suppl XXII):10. ">Owen 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>―</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>―</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1051/1410 (75%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0001" title="AgrawalRK , AlhassoA , Barrett‐LeePJ , BlissJM , BlissP , BloomfieldD , et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer. Radiotherapy and Oncology2011;100(1):93‐100. [DOI: 10.1016/j.radonc.2011.06.026.] BruntAM , SydenhamM , BlissJ , ColesC , GothardL , HarnettA , et al. A 5‐fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the UK‐FAST Trial (ISRCTN6248883, CRUKE/09/015). European Journal of Cancer Supplement. 2009; Vol. 7:3. NCT00107497 . Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control ‐ FAST. clinicaltrials.gov/ct2/show/NCT00107497?term=breast+cancer&amp;titles=FAST&amp;rank=5 (accessed 13/05/15). SydenhamM , HavilandJ , DonovanE , VenablesK , BlissJM , YarnoldJ , on behalf of the FAST Trial Management Group. Further testing of radiotherapy hypofractionation (fewer, larger fractions) in early breast cancer ‐ The FAST Trial. NCRI Cancer Conference. 2006. TsangY , HavilandJ , VenablesK , YarnoldJ , FAST Trial Management Group. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiotherapy and Oncology2012;104(2):143‐7. TsangYM , VenablesK , SydenhamM , on behalf of the FAST Working Party. Interim quality assurance (QA) analysis of treatment plans in the 'Faster Radiotherapy for Breast Cancer patients' (FAST) Trial. NCRI Cancer Conference. 2006. YarnoldJ . Prospective randomised trial testing 5.7 Gy and 6.0 Gy fractions of whole‐breast radiotherapy in women with early breast cancer (FAST Trial). Clinical Oncology. 2004; Vol. 16, issue 6:P3.02. ">FAST 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/729 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0009" title="BaneAL , WhelanTJ , PondGR , ParpiaS , GohlaG , FylesAW , et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology2014;25(5):992‐8. ClarkeRM , WhelanT , LevineM , RobertsR , WillanA , McCullochP , et al. Randomised clinical trial of breast irradiation following lumpectomy and axillary dissection for node‐negative breast cancer: an update. Journal of the National Cancer Institute1996;88:1659‐64. [NCT00156052] OCOG (Ontario Cooperative Oncology Group). A randomised trial of hypofractionated radiotherapy post‐lumpectomy in node negative breast cancer (study protocol). Unknown1992. WhelanT , MackenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. WhelanTJ , MackenzieRG , LevineM , ShelleyW , JulianJ , GrimardL , et al. A randomised trial comparing two fractionation schedules for breast irradiation post‐lumpectomy in node‐negative breast cancer. Proceedings of the Society of Clinical Oncology. 2000; Vol. 19, issue 2a. WhelanTJ , PignolJ , JulianJ , GrimardL , BowenJ , PereraF , et al. Long‐term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node‐negative breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2008; Vol. 72, issue 1:S28. WhelanTJ , PignolJP , LevineMN , JulianJA , MacKenzieR , ParpiaS , et al. Long‐term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine2010;362(6):513‐20. ">Whelan 2002b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1234 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0004" title="SahaS , Ghosh DastidarA , GangopadhyayA , GhoraiS . Evaluation of Hypofractionated Adjuvant Radiotherapy for Early Breast Cancer: A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 2009; Vol. 75. ">Saha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41/47 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0008" title="TaherAN , El‐BaradieMM , EssaH , ZakiO , EzzatS . Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reaction and cosmetic results. Journal of the Egyptian National Cancer Institute2004;16(3):178‐87. ">Taher 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/30 (50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0005" title="ShaitelmanSF , BuchholzTA , HuntKK , HortobagyiGN , SchlembachP , ArzuI , et al. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole beast irradiation: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90, issue 5:1265. ShaitelmanSF , SchlembachPJ , ArzuI , BalloM , BloomES , BuchholzD , et al. Acute and short‐term toxic effects of conventionally fractionated vs hypofractionated whole breast irradiation a randomized clinical trial. JAMA Oncology 2015 (accessed 06/08/15), issue Published online 06/08/15:E1‐E1111. [DOI: 10.1001/jamaoncol.2015.2666] ">Shaitelman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138/138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149/149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287/287 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003860-bbs2-0003" title="PatniN , JainM , PatniS , BapnaA . A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2012; Vol. 84:3. ">Patni 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Total number boosted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3454/7715 (44%)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Boost for women treated with breast conservation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Cosmesis scale (Owen 2006a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast Cosmesis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Cosmesis scale (Owen 2006a)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003860-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ASTRO 'suitable' patients for hypofractionated whole breast radiotherapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient is 50 years or older at diagnosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pathologic stage is T1–2 N0 and patient has been treated with breast conserving surgery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient has not been treated with systemic chemotherapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within the breast along the central axis, the minimum dose is no less than 93% and maximum dose is no greater than 107% of the prescription dose (7%;) (as calculated with 2‐dimensional treatment planning without heterogeneity corrections) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>T: tumour<br/> N: lymph node </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ASTRO 'suitable' patients for hypofractionated whole breast radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/full#CD003860-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003860-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypofractionation versus conventional fractionation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Local recurrence‐free survival (LR‐FS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 LR‐FS at median 3.5 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.03, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 LR‐FS at median 10 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LR‐FS by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 EQD2 less than 50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 EQD2 dose ≥ 50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cosmesis (fair/poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival (OS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 OS at 10 years median follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acute skin radiation toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.22, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Late skin toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Late skin RT toxicity at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.60, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Late subcutaneous toxicity (fibrosis)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Subcutaneous skin toxicity at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Subcutaneous skin toxicity at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Telangiectasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Breast oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.51, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Breast shrinkage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Ischaemic heart disease (left‐sided tumours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.28, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Rib fractures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.25, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Breast cancer‐specific survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Relapse‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Relapse‐free survival at median 5 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.81, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Relapse‐free survival at 10 years median follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypofractionation versus conventional fractionation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003860.pub4/references#CD003860-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003860.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003860-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003860-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003860-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003860-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003860-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="pt#CD003860-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003860-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003860-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003860\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003860\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003860\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003860\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003860.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003860.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003860.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003860.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003860.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729446089"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003860.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729446093"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003860.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edd116ae4bd65',t:'MTc0MDcyOTQ0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 